<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>276</serviceExecutionTime><Trial id="19076"><TitleDisplay>Compare How Effective Standard Dose Proton Pump Inhibitor (PPI) and Low Dose Tricyclic Antidepressant and Double Dose PPI to Standard Dose PPI and Placebo</TitleDisplay><TitleOfficial>Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CLIN-022-04F</Identifier><Identifier type="NCT">NCT00539240</Identifier></Identifiers><Indications><Indication id="1243">Gastroesophageal reflux</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>nortriptyline</Name></Intervention><Intervention type="InterventionPrimary"><Name>rabeprazole</Name><Drug id="2997">rabeprazole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2997">rabeprazole</Drug><IndicationsPioneer/><Companies><Company><Company id="26104">US Department of Veterans Affairs</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2997" type="Drug"><TargetEntity id="143151" type="siDrug">Rabeprazole sodium</TargetEntity></SourceEntity><SourceEntity id="26104" type="Company"><TargetEntity id="8589934520" type="organizationId">US Department of Veterans Affairs</TargetEntity></SourceEntity><SourceEntity id="1243" type="ciIndication"><TargetEntity id="K21" type="ICD10"/><TargetEntity id="530.81" type="ICD9"/><TargetEntity id="10017885" type="MEDDRA"/><TargetEntity id="D005764" type="MeSH"/><TargetEntity id="-837084427" type="omicsDisease"/><TargetEntity id="389" type="siCondition"/></SourceEntity><SourceEntity id="208" type="Action"><TargetEntity id="434" type="Mechanism">H+/K+-ATPase Inhibitors</TargetEntity><TargetEntity id="2955" type="Mechanism">Reversible H+/K+-ATPase Inhibitors </TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="26104">US Department of Veterans Affairs</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="208">H+ K+ ATPase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1594">Antibacterial</Class><Class id="182">Gastric secretion inhibitor</Class><Class id="2953">Anti-inflammatory</Class><Class id="38200">Acid pump inhibitor antiulcerant product</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>236</PatientCountEnrollment><DateStart>2006-04-30T00:00:00Z</DateStart><DateEnd type="actual">2011-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-30T10:11:13Z</DateChangeLast><DateAdded>2008-07-03T12:01:36Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Southern Arizona VA Health Care System, Tucson</Affiliation><Name>Ronnie Fass</Name></Contact><Contact type="Scientific contact"><Affiliation>SAVAHCS</Affiliation><Name>Ronnie Fass</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Currently being treated with a PPI, but continue to experience GERD symptoms (such as heartburn) at least two times per week&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known allergy or intolerance to TCA&lt;/li&gt;&lt;li&gt;Use of antidepressant or a diagnosis of depression&lt;/li&gt;&lt;li&gt;History of serious arrhythmia or use of anti-arrhythmics&lt;/li&gt;&lt;li&gt;History of seizures&lt;/li&gt;&lt;li&gt;Subjects with significant co-morbidity, eg, cardiovascular, respiratory, urogential, renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric&lt;/li&gt;&lt;li&gt;With evidence or history of drug abuse within the past 6 months&lt;/li&gt;&lt;li&gt;Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or adenocarcinoma of the esophagus on endoscopy&lt;/li&gt;&lt;li&gt;History of esophagogastric surgery&lt;/li&gt;&lt;li&gt;Gastric or duodenal lesions (ulcer, tumor, etc)&lt;/li&gt;&lt;li&gt;Women who are pregnant or of childbearing age who are not on contraception&lt;/li&gt;&lt;li&gt;Patients who are unwilling or unable to provide informed consent&lt;/li&gt;&lt;li&gt;Insulin dependent diabetes&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Daytime heartburn, number of days in week symptoms intensity score &lt; 3 (better): the number of days with Symptom Intensity Score &lt; 3 (better) for daytime heartburn during week 6 as compared to baseline</Description><Timeframe>Symptom control after 6 weeks of treatment</Timeframe></Measure><Measure><Description>Nighttime heartburn, number of days in week symptom activity score &lt;3 (better) in week 6 compared to baseline: the number of days with Symptom Intensity Score &lt; 3 (better) for nighttime heartburn during week 6 as compared to baseline</Description><Timeframe>Symptom control after 6 weeks of treatment</Timeframe></Measure><Measure><Description>Acid regurgitation, number of days in week symptoms intensity score &lt; 3 (better): the number of days with Symptom Intensity Score &lt; 3 (better) for acid regurgitation during week 6 as compared to baseline</Description><Timeframe>Symptom control after 6 weeks of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Health related quality of life: SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 to 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean</Description><Timeframe>End of study</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this project was to compare the efficacy (how successful) of   standard-dose proton pump inhibitor (PPI) &lt;ulink linkType="Drug" linkID="2997"&gt;rabeprazole&lt;/ulink&gt; 20 mg qd plus low dose tricyclic antidepressant nortriptyline 50 mg (TCA);  double-dose PPI &lt;ulink linkType="Drug" linkID="2997"&gt;rabeprazole&lt;/ulink&gt; 20 mg bid to standard-dose PPI &lt;ulink linkType="Drug" linkID="2997"&gt;rabeprazole&lt;/ulink&gt; 20 mg qd and placebo to determine the relative symptom resolution and health-related quality to compare the efficacy of 1) standard dose PPI plus low-dose TCA to 2) double dose PPI to 3) standard dose PPI and placebo life in gastroesophageal reflux disease (GERD) patients who failed standard-dose PPI. Patients   would  be randomly assigned to one of the three groups.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would   clarify for the first time the role of pain modulation in patients who failed standard dose of PPI.  The clinical experience with doubling the PPI dose, which was  the current standard of care, had  been very limited and relatively disappointing.  Additionally, this study may identify the group of PPI failure patients that may benefit from doubling the dose of PPI and the group that  benefits more from adding a pain modulator.  This study would be  timely, had never been performed and addresses a prevalent emerging clinical dilemma in GI as well as primary care clinics.&lt;br/&gt;Patients were randomized as follows:&lt;br/&gt;Arm 1: patients would receive rabeprazole 20 mg bid in brakfast and dinner and placebo bedtime.&lt;br/&gt;Arm 2:  patients would receive rabeprazole 20 mg, qd matching placebo twice daily at dinner , placebo for tricyclic antidepressant at bedtime.&lt;br/&gt;Arm 3:   patients would receive rabeprazole 20 mg, qd  (breakfast) study medication, dinner placebo once daily medication, tricyclic antidepressant at bedtime&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Southern Arizona VA Health Care System, Tucson</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85723</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Gastroesophageal reflux</Disease><PatientSegments><PatientSegment><PatientSegment id="9409">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8419">Subjects with Visceral Pain</PatientSegment><SubSegments><SubSegment id="8421">Subjects with abdominal pain</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00539240</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Gastroesophageal reflux" id="17663"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25924"><Endpoint>Assessment of Visceral Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25926">Assessment of abdominal pain</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Gastroesophageal reflux" id="16520"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="16521">Subjects with heartburn</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastroesophageal reflux" id="16575"><Criterion>Subjects with Protocol Specified Disease/Symptom Duration</Criterion></Inclusion><Inclusion disease="Gastroesophageal reflux" id="16577"><Criterion>Subjects with Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="16579">Subjects refractory to pump inhibitors (PPI) therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22134"><Criterion>Subjects with Visceral Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22136">Subjects with non-cardiac chest pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22197">Subjects with gastrointestinal diseases/disorder associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22210"><Criterion>Subjects with History/Scheduled for Pharmacological Therapy</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Gastroesophageal reflux" id="13668"><Criterion>Subjects with Diagnosis of GERD</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13674">Subjects with complications of GERD</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13690"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13691">Subjects with neurological/neuropsychiatric diseases/disorders</SubCriterion><SubCriterion disease="Gastroesophageal reflux" id="13700">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13692"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13695"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13696"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13698"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13721"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13727"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13734">Subjects with history of major surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="13736"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20121">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20120"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20177">Subjects with history/scheduled to undergo surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="25880"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13699">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="26041"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13694">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroesophageal reflux" id="27070"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Gastroesophageal reflux" id="13693">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>50.06 Months</EnrollmentPeriod><EnrollmentRate>4.71 Patients/Month</EnrollmentRate><DateFirstReceived>2007-10-03T00:00:00Z</DateFirstReceived><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-07-03T12:01:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="220014"><TitleDisplay>Evaluation of Post-Operative Recovery in Attune Total Knee Arthroplasty</TitleDisplay><TitleOfficial>Multicenter Evaluation of Post-Operative Recovery in Attune Primary, Cemented Total Knee Arthroplasty</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02339610</Identifier><Identifier type="Organisational Study">13005</Identifier></Identifiers><Indications><Indication id="542">Joint disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Attune implant</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1006039" type="Company"><TargetEntity id="5035532125" type="organizationId">Depuy Orthopaedics Inc</TargetEntity></SourceEntity><SourceEntity id="542" type="ciIndication"><TargetEntity id="10003285" type="MEDDRA"/><TargetEntity id="D007592" type="MeSH"/><TargetEntity id="-428607579" type="omicsDisease"/><TargetEntity id="2295" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1006039">DePuy Orthopaedics Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2015-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-28T00:00:00Z</DateEnd><DateChangeLast>2019-04-26T02:09:39Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>DePuy Orthopaedics</Affiliation><Name>Verdonna Huey, MS, BSN, CCRP</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is male or female and between the ages of 22 and 80 years at the time of surgery, inclusive&lt;/li&gt;&lt;li&gt;Subject was diagnosed with Non-inflammatory Degenerative Joint Disease (NIDJD)&lt;/li&gt;&lt;li&gt;Subject is a suitable candidate for cemented primary total knee replacement (TKA) using the devices described in this protocol with either resurfaced or non-resurfaced patellae&lt;/li&gt;&lt;li&gt;Subject has given voluntary, written informed consent to participate in this clinical investigation and has authorized the transfer of his/her information to the study sponsor&lt;/li&gt;&lt;li&gt;Subject is currently not bedridden&lt;/li&gt;&lt;li&gt;Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow- up visits and co-operate with investigational procedures&lt;/li&gt;&lt;li&gt;Subject is able to speak, read, and comprehend the informed consent document as well as complete the patient reported outcomes questionnaires required per the protocol in either Dutch or English translations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The subject is a woman who is pregnant or lactating&lt;/li&gt;&lt;li&gt;Contralateral knee has already been enrolled in this study&lt;/li&gt;&lt;li&gt;Subject had a contralateral amputation&lt;/li&gt;&lt;li&gt;Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee&lt;/li&gt;&lt;li&gt;Subject is currently experiencing radicular pain from the spine that radiates into the limb to receive TKA&lt;/li&gt;&lt;li&gt;Subject has participated in a clinical investigation with an investigational product (drug or device) in the last 3 months&lt;/li&gt;&lt;li&gt;Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims&lt;/li&gt;&lt;li&gt;Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last five years) or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements&lt;/li&gt;&lt;li&gt;Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia&lt;/li&gt;&lt;li&gt;Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing (eg, muscular dystrophy, multiple sclerosis, Charcot disease)&lt;/li&gt;&lt;li&gt;Subject is suffering from inflammatory arthritis (eg, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc)&lt;/li&gt;&lt;li&gt;Subject has a medical condition with  less than   three years of life expectancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>KOOS-PS change from baseline at 6 months post-operatively, as estimated from a repeated measurements longitudinal model over all post-operative time points: the knee injury and osteoarthritis physical function short form (KOOS-PS) will be used to measure knee function as a means of evaluating the rate of recovery. The (KOOS-PS) is a patient self-administered questionnaire. The questionnaire consists of seven questions to evaluate function with activities of daily living (ADL) and higher level functioning activities (sport and recreational). Each question has five likert-like response options. Scoring is a 0 to 100 point scale with 100 points considered best</Description><Timeframe>6 months post-operative minus pre-op</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Annual survivorship: a Kaplan-Meier survival analysis will be used to calculate the survivorship of the ATTUNE implant</Description><Timeframe>One year (304 to 669 days), two years (670 to 913 days) post-operative</Timeframe></Measure><Measure><Description>KOOS-PS change from baseline of the Attune knee: the Knee Injury and Osteoarthritis Physical Function Short Form (KOOS-PS) will be used to measure knee function as a means of evaluating the rate of recovery. The (KOOS-PS) is a patient self-administered questionnaire. The questionnaire consists of seven questions to evaluate function with activities of daily living (ADL) and higher level functioning activities (sport and recreational). Each question has five likert-like response options Scoring is a 0-100 point scale with 100 points considered best</Description><Timeframe>Pre-op (-90 days to day of surgery), 6 weeks (1 to 60 days), 3 months (61 to 137 days), one year (304 to 669 days), and two years (670 to 913 days) post-operative</Timeframe></Measure><Measure><Description>Length of hospital stay: collect days of hospitalization related to TKA procedure</Description><Timeframe>Immediate-post-operative: average 1 week</Timeframe></Measure><Measure><Description>Type and frequency of adverse events (AEs) for all enrolled subjects: all serious AEs must be reported to the sponsor per protocol. All device-related and/or procedure-related AEs must be reported to the sponsor per protocol</Description><Timeframe>Day 0 - post-operative day 913</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this  prospective, multicenter, non-randomized, non-comparative,      non-controlled, post-marketing investigational study is to  evaluate the rate of recovery of the Attune knee from      the time of surgery through the 6 month endpoint in patients with severely painful and/or      severely disabling non-inflammatory degenerative joint disease (NIDJD).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will undergo a primary total knee replacement using one of the four implant configurations of the Attune knee:  cruciate retaining fixed bearing (CR      FB), cruciate retaining rotating platform (CR RP), posterior stabilized fixed bearing (PS      FB), and posterior stabilized rotating platform (PS RP).&lt;/para&gt;&lt;para&gt;This study will allow the participating surgeon to choose the type of Attune implant that will be       ordinarily used in standard practice.  Both resurfaced patellae and non-resurfaced patellae      are permitted in this investigation; consistent with the surgeons standard of care.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Name>HAGA Hospital Orthopaedic Department</Name><Address1>The Hague</Address1><Address2>South Holland</Address2><Address3>2566</Address3><CountrySubDivision>South Holland</CountrySubDivision><Contacts/></Site><Site><Name>Lievensberg Hospital Orthopaedic Department</Name><Address1>Bergen op Zoom</Address1><Address2>North Brabant</Address2><Address3>4624</Address3><CountrySubDivision>North Brabant</CountrySubDivision><Contacts/></Site><Site><Name>Rijnstate Hospital - Orthopaedic Department</Name><Address1>Arnhem</Address1><Address2>Gelderland</Address2><Address3>6800</Address3><CountrySubDivision>Gelderland</CountrySubDivision><Contacts/></Site><Site><Name>Spaarne Hospital Orthopaedic Department</Name><Address1>Hoofddorp</Address1><Address2>North Holland</Address2><Address3>2134</Address3><CountrySubDivision>North Holland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02339610</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Anticipated">2019-06-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>26.00 Months</EnrollmentPeriod><EnrollmentRate>7.69 Patients/Month</EnrollmentRate><DateFirstReceived>2014-11-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-03-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="307970"><TitleDisplay>Analysis of Sweat Secretions and Body Dehydration Monitor</TitleDisplay><TitleOfficial>Spectrophon Dehydration Body Monitor Accuracy Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03229109</Identifier><Identifier type="Organisational Study">04/17</Identifier></Identifiers><Indications><Indication id="2225">Hyperhidrosis</Indication></Indications><BiomarkerNames><BiomarkerName id="44975" role="Therapeutic effect marker" type="Physiological">Sweat rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Spectrophon dehydration body monitor</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1072191" type="Company"><TargetEntity id="5037658945" type="organizationId">Tirat Carmel Mental Health Center</TargetEntity></SourceEntity><SourceEntity id="1095290" type="Company"><TargetEntity id="5042266864" type="organizationId">Ariel University of Samaria</TargetEntity></SourceEntity><SourceEntity id="2225" type="ciIndication"><TargetEntity id="R61" type="ICD10"/><TargetEntity id="10020642" type="MEDDRA"/><TargetEntity id="D006945" type="MeSH"/><TargetEntity id="-982941024" type="omicsDisease"/><TargetEntity id="1230" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1072191">Tirat Carmel Mental Health Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1095290">Ariel University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2017-05-03T00:00:00Z</DateStart><DateEnd type="actual">2017-07-27T00:00:00Z</DateEnd><DateChangeLast>2017-08-16T06:22:14Z</DateChangeLast><DateAdded>2017-08-09T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bruce Rappaport Medical Faculty, Technion, Haifa, Israel</Affiliation><Name>Anatoly Kreinin, MD, PHD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt; 18, both gender&lt;/li&gt;&lt;li&gt;Ability and willingness to sign an informed consent form for participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of cardiologic or vascular disease&lt;/li&gt;&lt;li&gt;Evidence of any other serious medical disorder&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Sweat rate: the volume of sweat produced during exertion</Description><Timeframe>90 min</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Total salt: total salt in sweat produced during exertion</Description><Timeframe>90 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to      estimate the accuracy of Spectrophon dehydration body monitor (DBM) incorporated in      smartwatch Samsung Gear S2 and sport band Samsung Gear Fit2 by comparing data obtained by DBM      with the total weight lost during exertion. The secondary      aim of the study is to evaluate the safety-in-use of Spectrophon DBM.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Healthy adults (n = 200) in different age and gender groups would be      recruited for the study. Samsung Gear S2 smartwatch with Spectrophon DBM attached to the      bottom of the smartwatch would be placed on the right wrist of each participant. At the same      time, Samsung Gear Fit2 sport band with Spectrophon DBM attached to the bottom of the band      would be placed on the left wrist of the participant. Each participant would be subjected to moderate      physical activity. Data from Samsung Gear S2 and Samsung Gear Fit2 would be obtained      simultaneously. In parallel, participant weight would also be monitored using commercially available      digital balancers (Shekel B-200-P).&lt;/para&gt;&lt;para&gt;The evaluation of the measurement accuracy of the Spectrophon DBM would be defined as the      difference between participant weight change during the exertion (due to sweating and water      consumption) and the volume of sweat detected by Spectrophon DBM. Participants would be weighed prior to the experiment (no clothing after maximal      drying) and then subjected to physical activity (walking on the treadmill). Total duration of study would be 90 min.&lt;/para&gt;&lt;para&gt;Participants would choose high or low intensity of exertion: high: up to 6.5km/h, low: yo to 6.0km/h. After DBM application was activated, DBM would start           recording data (sweat rate and total salt in sweat) every 20 s and automatically           save results into archive on a mobile phone linked to Samsung Gear S2 or Samsung Gear           Fit2 by Bluetooth. Manual recording of data would be conducted during breaks Participants           would also be weighed during each break (no clothing after maximal drying).&lt;/para&gt;&lt;para&gt;During the procedure, participants would drink up to 500 ml of water. The weight of      the bottle would be measured and recorded after drinking during breaks. The difference would be      subtracted to the weight loss calculation.&lt;/para&gt;&lt;para&gt;In this experiment, the following was avoided: urination during test (empty before T0) and weight loss should not exceed 2%. Participants would cancel the experiment at any point of the procedure if desired.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Israel"><Sites><Site><Name>Mental Health Center</Name><Address1>Tirat Karmel</Address1><Address2>Haifa</Address2><Address3>30200</Address3><CountrySubDivision>Haifa</CountrySubDivision><Contacts/></Site><Site><Name>Tirat Carmel Mental Health Center</Name><Address1>Tirat Karmel</Address1><Address2>Haifa</Address2><Address3>30200</Address3><CountrySubDivision>Haifa</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="15300">Others</PatientSegment><SubSegments><SubSegment id="17317">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16008">Subjects with Hyperhidrosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03229109</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other dermatological disease" id="42862"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33235">Subjects with hyperhidrosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other dermatological disease" id="34310"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33091">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other dermatological disease" id="34635"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="32831">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="23963"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24776">Subjects with cardiac diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="24216"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="24956"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24367">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-07-27T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-07-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="33441"><TitleDisplay>Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder</TitleDisplay><TitleOfficial>Improving Outcomes in Pharmacotherapy of Social Phobia</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">R01MH070919</Identifier><Identifier type="Organisational Study">R01 MH70919</Identifier><Identifier type="NCT">NCT00282828</Identifier><Identifier type="Secondary Organisational">PA-01-123</Identifier><Identifier type="Secondary Organisational">DSIR 83-ATAS</Identifier></Identifiers><Indications><Indication id="3150">Social phobia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sertraline</Name><Drug id="15183">sertraline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>clonazepam</Name><Drug id="44287">clonazepam</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sertraline</Name><Drug id="15183">sertraline</Drug></Intervention><Intervention type="InterventionPrimary"><Name>venlafaxine hydrochloride</Name><Drug id="4648">venlafaxine hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15183">sertraline</Drug><IndicationsPioneer/><Companies><Company><Company id="1039583">The National Institute of Mental Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21569">Massachusetts General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15183">sertraline</Drug><IndicationsPioneer/><Companies><Company><Company id="1039583">The National Institute of Mental Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21569">Massachusetts General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44287">clonazepam</Drug><IndicationsPioneer><Indication id="3150">Social phobia</Indication></IndicationsPioneer><Companies><Company><Company id="1039583">The National Institute of Mental Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21569">Massachusetts General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4648">venlafaxine hydrochloride</Drug><IndicationsPioneer/><Companies><Company><Company id="1039583">The National Institute of Mental Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21569">Massachusetts General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4648" type="Drug"><TargetEntity id="100721" type="siDrug">Venlafaxine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="15183" type="Drug"><TargetEntity id="167978" type="siDrug">Sertraline hydrochloride</TargetEntity><TargetEntity id="167978" type="siDrug">Sertraline hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44287" type="Drug"><TargetEntity id="91391" type="siDrug">Clonazepam</TargetEntity></SourceEntity><SourceEntity id="1039583" type="Company"><TargetEntity id="5035525475" type="organizationId">National Institute of Mental Health</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="3150" type="ciIndication"><TargetEntity id="F40.1" type="ICD10"/><TargetEntity id="10041250" type="MEDDRA"/><TargetEntity id="-999270457" type="omicsDisease"/><TargetEntity id="36" type="siCondition"/></SourceEntity><SourceEntity id="1198" type="Action"><TargetEntity id="5774" type="Mechanism">GABA(A) Receptor Ligands</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1039583">The National Institute of Mental Health</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1198">GABA receptor modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class><Class id="3">5-HT uptake inhibitor</Class><Class id="70">Anticonvulsant agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>397</PatientCountEnrollment><PatientCountEvaluable>346</PatientCountEvaluable><DateStart>2006-03-31T00:00:00Z</DateStart><DateEnd type="actual">2011-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-12T15:23:03Z</DateChangeLast><DateAdded>2008-11-13T06:46:02Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of California San Diego; La Jolla; California; 92093; United States</Affiliation><Name>Laura Campbell-Sills</Name></Contact><Contact type="Public contact"><Affiliation>University of California San Diego; La Jolla; California; 92093; United States</Affiliation><Name>Denise Chavira</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Name>David Dorer</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Email>lefischer@partners.org</Email><Name>Laura Fischer</Name><Phone>617-726-1570</Phone></Contact><Contact type="Public contact"><Affiliation>University of California San Diego; La Jolla; California; 92093; United States</Affiliation><Name>Ann Fleming</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Email>nherlands@partners.org</Email><Name>Nannette Herlands</Name><Phone>617-736-1570</Phone></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Name>Elizabeth Hoge</Name></Contact><Contact type="Public contact"><Affiliation>McMaster University Medical Centre; Hamilton; Ontario; L8N 3Z5; Canada</Affiliation><Name>Catherine Mancini</Name></Contact><Contact type="Public contact"><Affiliation>University of California San Diego; La Jolla; California; 92093; United States</Affiliation><Name>Scott Matthews</Name></Contact><Contact type="Public contact"><Affiliation>McMaster University Medical Centre; Hamilton; Ontario; L8N 3Z5; Canada</Affiliation><Name>Jonathan Oakman</Name></Contact><Contact type="Public contact"><Affiliation>McMaster University Medical Centre; Hamilton; Ontario; L8N 3Z5; Canada</Affiliation><Email>bpatter@mcmaster.ca</Email><Name>Beth Patterson</Name></Contact><Contact type="Public contact"><Email>eporter1@partners.org</Email><Name>Eliora Porter</Name><Phone>617-726-1570</Phone></Contact><Contact type="Public contact"><Affiliation>University of California San Diego; La Jolla; California; 92093; United States</Affiliation><Email>trobinson@ucsd.edu</Email><Name>Toni Robinson</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Name>David Schoenfeld</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Name>Naomi Simon</Name></Contact><Contact type="Public contact"><Affiliation>Center for Anxiety and Traumatic Stress Disorders; Boston; Massachusetts; 02116; United States</Affiliation><Name>John Worthington</Name></Contact><Contact type="Scientific contact"><Affiliation>Massachusetts General Hospital</Affiliation><Name>Mark Pollack</Name></Contact><Contact type="Scientific contact"><Affiliation>University of California San Deigo</Affiliation><Email>mstein@UCSD.Edu</Email><Name>Murray Stein</Name><Phone>858-534-6400</Phone></Contact><Contact type="Scientific contact"><Affiliation>Anxiety Disorders Clinic McMaster Univeristy Medical Centre</Affiliation><Name>Michael Ameringen</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Primary psychiatric diagnosis of GSAD as defined by DSM-IV criteria and a score above 60 on the LSAS&lt;/li&gt;&lt;li&gt;Agrees to use an effective form of contraception throughout the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Clinically significant abnormalities found upon physical examination, electrocardiogram, and laboratory tests&lt;/li&gt;&lt;li&gt;History of more than two unsuccessful, adequate treatment trials, indicated by a lack of response to over 10 weeks of any of the following: SSRIs (eg, 40 mg of paroxetine or its equivalent per day); benzodiazepine (eg, at least 2.5 mg of&lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; per day) plus antidepressant (adequate dose as above); monoamine oxidase inhibitors (eg, 60 mg of phenelzine or its equivalent per day); or a single failed trial of over 10 weeks of &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; (at least 150 mg per day)&lt;/li&gt;&lt;li&gt;Pregnant or breastfeeding&lt;/li&gt;&lt;li&gt;Simultaneous use of other psychotropic medications; participants must discontinue regular benzodiazepine or antidepressant therapy at least two weeks (5 weeks for fluoxetine) prior to study entry; beta-blockers must be discontinued unless they are indicated medically (eg, for hypertension)&lt;/li&gt;&lt;li&gt;DSM-IV diagnosis of any of the following: lifetime history of schizophrenia or any other psychosis, mental retardation, organic medical disorder, bipolar disorder, or obsessive compulsive disorder; eating disorder in the past 6 months; alcohol or substance abuse in the past 3 months or dependence within the past 6 months (entry of participants with major depression, dysthymia, panic disorder, generalized anxiety disorder, or post-traumatic stress disorder will be permitted if the social anxiety disorder is judged to be the predominant disorder)&lt;/li&gt;&lt;li&gt;Significant suicidal ideation as indicated by a score greater than  three on the Montgomery-Asberg Depression Rating Scale or suicidal behaviors within 6 months prior to study entry&lt;/li&gt;&lt;li&gt;Significant personality dysfunction that could interfere with study participation&lt;/li&gt;&lt;li&gt;Serious medical illness or instability for which hospitalization may be likely during the study&lt;/li&gt;&lt;li&gt;Seizure disorders, with the exception of a childhood history of isolated, non-recurrent febrile seizures&lt;/li&gt;&lt;li&gt;Any concurrent psychotherapy initiated within 3 months of study entry, or ongoing psychotherapy of any duration directed specifically toward treatment of GSAD (prohibited psychotherapy includes cognitive behavioral therapy or psychodynamic therapy that focuses on exploring specific, dynamic causes of the phobic symptomatology and that provides management skills; general supportive therapy for more than 3 months is acceptable)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Rates of remission (LSAS &lt;/= 30) after 12 weeks of randomized treatment during phase II, among phase I non-responders: the Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale assessing fear and avoidance in social and performance situations; it is widely used in studies of pharmacological treatment of Generalized Social Anxiety Disorder (GSAD). Scores on the LSAS range from 0 to 144, with higher scores indicating greater pathology</Description><Timeframe>Measured at week 22</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Post-treatment social phobia severity as defined by endpoint LSAS scores: the Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale assessing fear and avoidance in social and performance situations; it is widely used in studies of pharmacological treatment of Generalized Social Anxiety Disorder (GSAD). We analyzed the overall change in LSAS (last phase II LSAS minus week 10 LSAS). Higher numbers reflect greater drops in social anxiety disorder severity. Scores on the LSAS range from 0 to 144, with higher scores indicating greater pathology</Description><Timeframe>Change from week 10 to 22</Timeframe></Measure><Measure><Description>Predictors of efficacy were examined in multivariate regression models that included eight polymorphic variants in four candidate genes (4 in RGS2, 2 in HTR2A, 1 in SLC6A2, and 1 in SLC6A4).</Description></Measure><Measure><Description>Symptom remission rates and post-treatment social phobia severity</Description><Timeframe>Week 22</Timeframe></Measure><Measure><Description>Treatment response</Description><Timeframe>Week 10</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  compared the effectiveness of either adding &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; or placebo to standard treatment or switching to &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; in treating generalized social anxiety disorder (GSAD) in individuals who had not responded to treatment with &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in January 2014. Overall, remission was reported in 21% of the participants  (LSAS score &amp;lt;/= 30) at the endpoint, and  in 27% of participants assigned to &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; compared to participants assigned to &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo (17%) or &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; (19%), but the differences were not significant.   A significantly greater drop in LSAS severity (p = 0.020) and disability (p = 0.0028) was seen with &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; compared to &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo; there were no significant differences on these parameters between &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; and either &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo or &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt;. In supplemental analysis, the study reported an overall response rate (LSAS score &amp;lt;/= 50) of 46%, including a significantly greater proportion of patients in the &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; group (56%) compared to the &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo group responding (36%; p=  0.027). The differences were not significant between &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo or &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1516950"&gt;1516950&lt;/ulink&gt;]. Similar results were published [&lt;ulink linkType="Reference" linkID="1545063"&gt;1545063&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results published in May  2014 showed that all the four single nucleotide polymorphisms (SNP) in RSG2 predicted significant change in the LSAS (Social Anxiety Scale) over time (p = 0.00833) when adjusting for genetic ancestral cluster and non-genetic predictors of response, but the minor allele was found to have less improvement over time. It was observed that likelihood of remission at or just below study wise significance (p = 0.025) was predicted for two of the four RGS2 SNPs; ie, rs4606 (p = 0.022) and rs1819741 (p = 0.027), after adjusting for genetic ancestral cluster and non-genetic predictors of response [&lt;ulink linkType="Reference" linkID="1493247"&gt;1493247&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would also examine predictors of treatment response, including factors such as age at disease onset, duration of illness, comorbidities, and genes that influence serotonin and catecholamine metabolism.&lt;/para&gt;&lt;para&gt;Participants in this double-blind study would first partake in an initial 10-week phase in which they would be treated with &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;. Participants who do not respond to &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; treatment would proceed to phase two of the study, in which they would be randomly assigned to one of three treatment groups. &lt;br/&gt;One group would receive both &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt;, participants would take 0.5 to 3 mg per day of &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; for 12 weeks. Another group would receive both &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; and placebo, and the third group would receive only &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt;, participants would take 75 to 225 mg/day of &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt;  for 12 weeks. All treatments will continue for 12 weeks. All participants would attend weekly study visits at weeks 1, 2, 4, 6, 8, and 10. Participants who continue into phase two would attend weekly study visits at Weeks 11 to 14, 16, 18, 20, and 22. Symptom remission rates and post-treatment social phobia severity would be assessed at week 22.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;After a 10-week trial of &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; alone (n = 397), participants (n = 181) received additionally of up to 3.0 mg/day of &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt; (&lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="44287"&gt;clonazepam&lt;/ulink&gt;), a switch to up to 225 mg/day of &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt;, or prolonged &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; treatment with placebo (&lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; plus placebo) [&lt;ulink linkType="Reference" linkID="1516950"&gt;1516950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A total of 346 participants received &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt; upto 200 mg/day for over 10 weeks [&lt;ulink linkType="Reference" linkID="1493247"&gt;1493247&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="67068">clonazepam</Intervention><Treatments><Treatment><Dose>0.5 milligram</Dose><Route></Route></Treatment><Treatment><Dose>3 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="67146">sertraline</Intervention><Treatments><Treatment><Dose>200 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="67069">venlafaxine hydrochloride</Intervention><Treatments><Treatment><Dose>75 milligram</Dose><Route></Route></Treatment><Treatment><Dose>225 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>McMaster University Medical Centre Anxiety Disorders Clinic</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><Address3>L8N 3Z5</Address3><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>McMaster University Medical Centre Anxiety Disorders Clinic</Name><Address1>Hamilton</Address1><Address3> L8N 3Z5</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>University of California San Diego</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3>92093</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Center for Anxiety and Traumatic Stress Disorders</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02116</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Center for Anxiety and Traumatic Stress Disorders</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3> 2116</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>University of California - San Diego</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3> 92093</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anxiety disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7469">Subjects with Social Phobia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00282828</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anxiety disorder" id="10406"><Endpoint>Assessment of Symptoms of Social Anxiety Disorder</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10407">Assessment by Liebowitz Social Anxiety Scale [LSAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anxiety disorder" id="10513"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10514">Assessment of remission rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anxiety disorder" id="10510"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Anxiety disorder" id="46823"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="47331">SLC6A4_HUMAN_Mutation</SubEndpoint><SubEndpoint disease="Anxiety disorder" id="49817">HTR2A_HUMAN_Mutation</SubEndpoint><SubEndpoint disease="Anxiety disorder" id="49818">SLC6A2_HUMAN_Mutation</SubEndpoint><SubEndpoint disease="Anxiety disorder" id="49887">RGS2_HUMAN_Mutation</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anxiety disorder" id="6531"><Criterion>Subjects with a Specific Anxiety Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6535">Subjects with separation anxiety disorder</SubCriterion><SubCriterion disease="Anxiety disorder" id="6537">Subjects with phobic disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6540"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6541">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6569"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6574">Protocol specified scores of social anxiety assessment scales</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anxiety disorder" id="8165"><Criterion>Subjects with Clinical Diagnosis of Anxiety Disorders</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8171">Subjects with obsessive-compulsive disorder (OCD)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8173"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8177">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8179"><Criterion>Protocol Specified Scales of Anxiety Disorders Symptom Assessment</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8182">Protocol specified scores of protocol specified depression scales</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8183"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8184">Subjects with mood disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8185">Subjects co-morbid with psychotic disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8186">Subjects with eating disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8187">Subjects co-morbid with substance abuse disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8188">Subjects co-morbid with developmental disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8192">Subjects with Axis II disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8194"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8195">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8206"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8215"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8226"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8227">Subjects with history/scheduled to receive anti-depressants</SubCriterion><SubCriterion disease="Anxiety disorder" id="8228">Subjects with history of benzodiazepines</SubCriterion><SubCriterion disease="Anxiety disorder" id="8233">Subjects with history of psychotropic drugs</SubCriterion><SubCriterion disease="Anxiety disorder" id="8235">Subjects with history of psychotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8239"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8241">Subjects with history of cardiovascular medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8251"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2006-01-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-13T06:46:02Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-11-06T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="34765"><TitleDisplay>Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia</TitleDisplay><TitleOfficial>A Randomized, Double-Blind, Placebo-Controlled, Dose-Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">TH-CR-203</Identifier><Identifier type="NCT">NCT00237536</Identifier></Identifiers><Indications><Indication id="1241">Prostate hyperplasia</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Disease marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lonidamine</Name><Drug id="6410">lonidamine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6410">lonidamine</Drug><IndicationsPioneer/><Companies><Company><Company id="30181">Molecular Templates Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6410" type="Drug"><TargetEntity id="90137" type="siDrug">Lonidamine</TargetEntity></SourceEntity><SourceEntity id="30181" type="Company"><TargetEntity id="4295908364" type="organizationId">Molecular Templates Inc</TargetEntity></SourceEntity><SourceEntity id="1241" type="ciIndication"><TargetEntity id="10051482" type="MEDDRA"/><TargetEntity id="D011470" type="MeSH"/><TargetEntity id="-1410482198" type="omicsDisease"/><TargetEntity id="362" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><NumberOfSites>34</NumberOfSites><CompaniesSponsor><Company id="30181">Molecular Templates Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="6777">Hexose kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1569">Anticancer antimetabolite</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>240</PatientCountEnrollment><PatientCountEvaluable>216</PatientCountEvaluable><DateStart>2005-06-30T00:00:00Z</DateStart><DateEnd type="actual">2006-08-01T00:00:00Z</DateEnd><DateChangeLast>2019-03-07T16:21:00Z</DateChangeLast><DateAdded>2008-11-17T07:05:41Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Capable of understanding the purpose and risks of the study and sign a statement of informed consent&lt;/li&gt;&lt;li&gt;Male 65 to 80 years of age (or 40 to 80 with vasectomy). Vasectomized men must have documentation of  azoospermia&lt;/li&gt;&lt;li&gt;Presence of LUTS (lower urinary tract symptoms) for at least 3 months&lt;/li&gt;&lt;li&gt;Prostate volume measured by TRUS (transrectal ultrasound)&amp;gt; 30 cc&lt;/li&gt;&lt;li&gt;Qmax&amp;lt; 15 ml/s when measured by uroflowmetry (minimum of 125 ml must be voided)&lt;/li&gt;&lt;li&gt;IPSS (International Prostate Symptom Score)&amp;gt; 12&lt;/li&gt;&lt;li&gt;PSA&amp;gt; 1.0 ng/ml&lt;/li&gt;&lt;li&gt;Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential&lt;/li&gt;&lt;li&gt;Able to comply with the prescribed treatment protocol and evaluations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior treatment for BPH with alpha blockers and/or herbal supplements for the treatment of BPH in the past 2 weeks (alpha-blockers and/or herbal supplements for the treatment of BPH are not allowed during the study).  Prior treatment with 5-alpha reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment&lt;/li&gt;&lt;li&gt;Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)&lt;/li&gt;&lt;li&gt;Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (For subjects with PSA between 4 to 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator.  Subjects with PSA&amp;gt;10 ng/ml are excluded)&lt;/li&gt;&lt;li&gt;Active urinary tract infections (UTI)&lt;/li&gt;&lt;li&gt;Active cardiac, renal or hepatic disease as evidenced by:&lt;ul&gt;&lt;li&gt;Serum creatinine&amp;gt; 1.8 mg/dl&lt;/li&gt;&lt;li&gt;ALT or AST&amp;gt; 2.5 x the upper limit of normal&lt;/li&gt;&lt;li&gt;History of active myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months prior to screening&lt;/li&gt;&lt;li&gt;Uncontrolled congestive heart failure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Uncontrolled diabetes mellitus (fasting blood glucose&amp;gt; 200 mg/dl)&lt;/li&gt;&lt;li&gt;Use of systemic steroids for any reason (systemic steroid usage is not allowed during the study).  Inhaled and/or topical steroids are allowed&lt;/li&gt;&lt;li&gt;Concurrent participation or participation in an investigational drug study within the past 30 days prior to screening&lt;/li&gt;&lt;li&gt;Concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the Investigator, pose an unacceptable risk to the subject&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>IPSS</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Maximum urinary flow rate (Qmax)</Description></Measure><Measure><Description>Post-void residual urine volume (PVR)</Description></Measure><Measure><Description>Prostate volume</Description></Measure><Measure><Description>Prostate specific antigen (PSA)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to evaluate the dose response relationship of &lt;ulink linkType="Drug" linkID="6410"&gt;lonidamine&lt;/ulink&gt; and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results showed that the  study did not meet the primary endpoint of symptomatic improvement as measured by IPSS (International Prostate Symptom Score) and did not generate a statistically significant dose response relationship. The interim analysis indicated that the drug did not demonstrate a clear dose response in IPSS at 1 month of treatment. The mean IPSS change from baseline as measured following placebo run-in to 1 month of treatment ranged from -2.1 to -2.5 across the five dose groups, including the placebo control. IPSS change from baseline (Mean [SD]) at 1 month for placebo (n = 40), 5 mg (n = 44), 25 mg (n = 43),   50 mg (n = 38), 150 mg (n = 40) were -2.1 (4.5) -2.3 (6.1) -2.5 (5.2) -2.2 (4.4) -2.3 (5.7) respectively [&lt;ulink linkType="Reference" linkID="678798"&gt;678798&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;After a 2-week placebo run-in period, 216 patients were randomized to receive placebo or one of four doses of &lt;ulink linkType="Drug" linkID="6410"&gt;TH-070&lt;/ulink&gt; (5, 25, 50, 150 mg) daily for 1 month and to be followed off therapy for 3 months. The primary objectives of this study were to determine the dose-response relationship of &lt;ulink linkType="Drug" linkID="6410"&gt;TH-070&lt;/ulink&gt; with respect to symptomatic improvement (as measured by IPSS) and to evaluate other efficacy endpoints and the safety at the different doses [&lt;ulink linkType="Reference" linkID="678798"&gt;678798&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;After a 2-week placebo run-in period, 216 patients were randomized to receive placebo or one of four doses of &lt;ulink linkType="Drug" linkID="6410"&gt;TH-070&lt;/ulink&gt; (5, 25, 50, 150 mg) daily for 1 month and to be followed off therapy for 3 months [&lt;ulink linkType="Reference" linkID="678798"&gt;678798&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="69984">lonidamine</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route></Route></Treatment><Treatment><Dose>25 milligram</Dose><Route></Route></Treatment><Treatment><Dose>50 milligram</Dose><Route></Route></Treatment><Treatment><Dose>150 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Advanced Clinical Therapeutics</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85712</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Stanford University Hospital</Name><Address1>Stanford</Address1><Address2>California</Address2><Address3>94305</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>San Diego Uro-Research</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92103</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Atlantic Urological Medical Group</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90806</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Chris B. Threatt, MD Inc.</Name><Address1>Atherton</Address1><Address2>California</Address2><Address3>94027</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Urological Sciences Research Foundation</Name><Address1>Culver City</Address1><Address2>California</Address2><Address3>90232</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>California Professional Research</Name><Address1>Newport Beach</Address1><Address2>California</Address2><Address3>92660</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Urology Research Options</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3>80012</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Connecticut Clinical Research Center Urology Specialists</Name><Address1>Waterbury</Address1><Address2>Connecticut</Address2><Address3>06708</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Tampa Bay Medical Research</Name><Address1>Clearwater</Address1><Address2>Florida</Address2><Address3>33761</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>South Florida Medical Research</Name><Address1>Aventura</Address1><Address2>Florida</Address2><Address3>33180</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Florida Healthcare Research</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3>34474</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Midwest Prostate &amp; Urology Health Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60640</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Specialty Care Research</Name><Address1>Peoria</Address1><Address2>Illinois</Address2><Address3>61614</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Metropolitan Urology</Name><Address1>Jeffersonville</Address1><Address2>Indiana</Address2><Address3>47130</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Northeast Indiana research, LLC</Name><Address1>Fort Wayne</Address1><Address2>Indiana</Address2><Address3>46825</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Werner, Murdock &amp; Francis, PA, Urology Associates</Name><Address1>Greenbelt</Address1><Address2>Maryland</Address2><Address3>20770</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Sheldon J. Freedman, MD Ltd.</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89109</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts/></Site><Site><Name>Lawrenceville Urology</Name><Address1>Lawrenceville</Address1><Address2>New Jersey</Address2><Address3>08648</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Delaware Valley Clinical Research</Name><Address1>Cherry Hill</Address1><Address2>New Jersey</Address2><Address3>08003</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Urology Healthcare Associates</Name><Address1>Westampton</Address1><Address2>New Jersey</Address2><Address3>08060</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>Accumed Research Associates</Name><Address1>Garden City</Address1><Address2>New York</Address2><Address3>11530</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>New York University School of Medicine</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Weill Medical College of Cornell University</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Radiant Research. Columbus</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43212</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>State College Urologic Associates</Name><Address1>State College</Address1><Address2>Pennsylvania</Address2><Address3>16801</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Urological Associates of Lancaster</Name><Address1>Lancaster</Address1><Address2>Pennsylvania</Address2><Address3>17604</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>University Urological Research Institute</Name><Address1>Providence</Address1><Address2>Rhode Island</Address2><Address3>02904</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><Contacts/></Site><Site><Name>Radiant Research, Greer</Name><Address1>Greer</Address1><Address2>South Carolina</Address2><Address3>29651</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Urology San Antonio Research</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Accelovance</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77024</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>UT Southwestern Medical Center at Dallas, Dept of Urology</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75390</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Baylor College of Medicine, Scott Department of Urology</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Integrity Medical Research, LLC</Name><Address1>Mountlake Terrace</Address1><Address2>Washington</Address2><Address3>98043</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate hyperplasia</Disease><PatientSegments><PatientSegment><PatientSegment id="11507">Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</PatientSegment><SubSegments><SubSegment id="11509">Subjects diagnosed by transrectal/abdominal ultrasound(TRUS)</SubSegment><SubSegment id="11510">Subjects diagnosed by prostate-specific antigen(PSA) test</SubSegment><SubSegment id="11513">Subjets with prostate volume &gt;20</SubSegment><SubSegment id="11514">Subjects with lower urinary tract symptoms(LUTS)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11516">Subjects Uroflowmetry Findings</PatientSegment><SubSegments><SubSegment id="11517">Subjets with maximum urine flow(Qmax) score</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11526">Subjects with Surgical Treatment</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="15518">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="11505">Subjets with Moderately Symptomatic BPH</SubSegment><SubSegment id="11506">Subjets with Severely Symptomatic BPH</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00237536</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate hyperplasia" id="22613"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22614">International prostate symptom score(IPSS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate hyperplasia" id="22626"><Endpoint>Assessment of Urodynamics</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22627">Assessment of  post void residual (PVR) urine volume</SubEndpoint><SubEndpoint disease="Prostate hyperplasia" id="22628">Uroflowmetry assessments</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22636"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22637">Prostate-specific antigen(PSA)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate hyperplasia" id="22642"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22643">Assessment of prostrate volume/size</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate hyperplasia" id="20360"><Criterion>Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="20362">Subjets with moderately symptomatic BPH</SubCriterion><SubCriterion disease="Prostate hyperplasia" id="20363">Subjets with severely symptomatic BPH</SubCriterion><SubCriterion disease="Prostate hyperplasia" id="20365">Subjects diagnosed by transrectal/abdominal ultrasound(TRUS)</SubCriterion><SubCriterion disease="Prostate hyperplasia" id="20366">Subjects diagnosed by prostate-specific antigen(PSA) test</SubCriterion><SubCriterion disease="Prostate hyperplasia" id="20369">Subjets with prostate volume &gt;20</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate hyperplasia" id="20371"><Criterion>Subjects with lower urinary tract symptoms(LUTS)</Criterion></Inclusion><Inclusion disease="Prostate hyperplasia" id="20373"><Criterion>Subjects Uroflowmetry Findings</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="20374">Subjets with maximum urine flow(Qmax) score</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate hyperplasia" id="20383"><Criterion>Subjects with Surgical Treatment</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate hyperplasia" id="17869"><Criterion>Subjects with Urinary Tract Infection</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17872"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="17873">Subjects co-morbid with prostate cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate hyperplasia" id="17876"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17879"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17880"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17882"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17898"><Criterion>Subjects with history of/scheduled for pharmacological therapy</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17927"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2006-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2005-10-10T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-17T07:05:41Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="359885"><TitleDisplay>Influence of Ozone Application in Stepwise Excavation Procedure of Primary Molars With Deep Carious Lesion</TitleDisplay><TitleOfficial>Ozone Application in Stepwise Excavation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03737201</Identifier><Identifier type="Organisational Study">213S004-2</Identifier></Identifiers><Indications><Indication id="3015">Dental caries</Indication></Indications><BiomarkerNames><BiomarkerName id="55817" role="Therapeutic effect marker" type="Structural (imaging)">Dentin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Heal ozone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ozone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>chlorhexidine digluconate</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>conventional pulp therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1034326" type="Company"><TargetEntity id="5035559158" type="organizationId">Turkiye Bilimsel ve Teknolojik Arastirma Kurumu</TargetEntity></SourceEntity><SourceEntity id="1085464" type="Company"><TargetEntity id="5040051416" type="organizationId">Izmir Katip Celebi Universitesi</TargetEntity></SourceEntity><SourceEntity id="3015" type="ciIndication"><TargetEntity id="K02" type="ICD10"/><TargetEntity id="10012318" type="MEDDRA"/><TargetEntity id="D003731" type="MeSH"/><TargetEntity id="-851804693" type="omicsDisease"/><TargetEntity id="1155" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1085464">Izmir Katip Celebi University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1034326">The Scientific and Technological Research Council of Turkey</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>105</PatientCountEnrollment><DateStart>2017-01-01T00:00:00Z</DateStart><DateEnd type="actual">2018-01-01T00:00:00Z</DateEnd><DateChangeLast>2018-11-17T05:05:28Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Izmir Katip Celebi University</Affiliation><Name>Merve AKCAY</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Previously untreated, vital and asymptomatic lower primary molars with deep caries lesions considered likely to result in pulp exposure if they were treated by a single and terminal excavation&lt;/li&gt;&lt;li&gt;Positive pulp sensibility tested by an electric pulp tester and cold stimulation&lt;/li&gt;&lt;li&gt;Mild discomfort from chemical and thermal stimuli&lt;/li&gt;&lt;li&gt;Cooperative children and parents willing to follow the instructions and report for follow-up&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Signs of irreversible pulpitis (spontaneous pain, prolonged pain response etc,)&lt;/li&gt;&lt;li&gt;The presence of percussion or palpation sensitivity, pathological mobility, or infection symptoms like fistula or abscess or discoloration in the clinical examination&lt;/li&gt;&lt;li&gt;Absence of normal lamina dura and periodontal range, presence of lesion, internal or external resorption or calcification in or around the root in the radiological examination&lt;/li&gt;&lt;li&gt;Children with special health care needs&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes microbiological count: from baseline to 4 months: Mutans streptococci counts were calculated</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure><Measure><Description>Changes microbiological count: from baseline to 4 months: Lactobacilli counts were calculated</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure><Measure><Description>Changes microbiological count: from baseline to 4 months: total number of colony forming units counts were calculated</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Changes characteristics of the dentin color: from baseline to 4 months: the colour of dentin was classified as, light yellow, yellow, light brown, dark brown/black</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure><Measure><Description>Changes characteristics of the dentin consistency: from baseline to 4 months: the consistency of dentin was determined by probing and classified as; very soft, soft, medium hard and hard</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure><Measure><Description>Changes characteristics of the dentin humidity: from baseline to 4 months: dentine was probed and if moisture leakage was occurred, it was classified as wet or if did not it would be classified as dry</Description><Timeframe>Baseline and 4 months later</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to investigate the clinical and microbiological      effectiveness of the ozone application in stepwise excavation of primary molars.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Informed consent including possible risks, discomforts and benefits about the procedure would be      obtained from all parents of the young patients. The required sample size for this study would be 35 in each subgroup (82 percent power, two-sided      five percent significance level) for the detection of a significant difference. This study      would be conducted on 105 patients aged 6 to 10 years (59 girls, 46 boys) who attended the      Pediatric Dentistry Department. None of the patients included in the study would be medically      compromised. Each patient would have one mandibular second primary molar with deep carious lesion      and pulp perforation risk. All teeth with deep carious lesions would be examined clinically and      radiographically. The following inclusion criteria would be used: active carious lesion in deep dentine of primary second molars, absence of clinical symptoms of irreversible pulpitis such as spontaneous pain or           longtime pain against thermal and chemical stimuli, absence of sensitivity to percussion or palpation, pathological mobility, swelling or           fistula any discoloration except for carious lesion and absence of any interradicular lesions, periapical radiolucency, pathological resorptions           and pulpal calcifications.&lt;/para&gt;&lt;para&gt;A randomized, controlled, clinical trial would be designed in a sample of 105 primary molars (35      teeth in each group) as three treatment groups: step-wise excavation without any disinfectant      (control group), step-wise excavation with chlorhexidine digluconate (CHX) application (positive control group), and      step-wise excavation with gaseous ozone application (experimental group).&lt;br/&gt;Control Group: After partial removal of carious dentin, calcium hydroxide, Ca(OH)2 base      material (Dycal; Dentsply International Milford, USA) would be placed on the remaining carious      dentin without applying any cavity disinfectants. A 35 molar teeth with deep caries lesion would be selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin would be completely removed, and left some caries at the central part. &lt;br/&gt;Positive Control Group: After partial removal of carious dentin, 2% CHX solution (Cavity      Cleanser, Bisco, USA) would be applied to the cavity for 60 s with an applicator brush for      disinfection procedure. According to the manufacturer instructions, puddled solution would be      removed with a new brush without dry to leave site moist. Then, Ca(OH)2 base (Dycal;      Dentsply) would be placed on the remaining carious dentin. A 35 molar teeth with deep caries lesion would be selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin would be completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate would be applied to the cavity for 60 s using a brush. &lt;br/&gt;Experimental Group: After partial removal of carious dentin, ozone gas (Heal ozone, KaVo      Dental, Germany) with the concentration of 2100 ppm would be applied to the cavity for 60 s for      disinfection procedure. Ozone production stopped if the airtight seal over the tooth would be      broken during treatment, therefore, silicon caps would be selected according to the size of each      tooth. And Ca(OH)2 base would be placed on the remaining carious dentin. A 35 molar teeth with deep caries lesion would be selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin would be completely removed, and left some caries at the central part. The cavity would be exposed to gaseous ozone for 60 seconds, with an ozone delivery system. &lt;/para&gt;&lt;para&gt;According to the manufacturer instructions, puddled solution would be removed with a new brush without dry to leave site moist. The remaining caries dentin would be covered with calcium hydroxide base material and cavity sealed with glass ionomer cement. In four different stages (after;      initial excavation, ozone/CHX application, 4 months, final excavation), dentine samples      would be collected for microbiological analysis of mutans streptococci, lactobacilli and total      number of colony forming units. Clinical changes as dentine colour, humidity, consistency      would be recorded. The data would be analysed by Mann-Whitney U, Friedman and chi-square test. All procedures would be performed by one investigator. After mandibular anesthesia of the tooth,      rubber dam isolation would be provided. Carious enamel, lateral walls of the cavity and necrotic      dentin would be removed with carbide burs. Removal of carious dentin would be performed with dentin      excavators and low speed-burs, and left some caries at the central part. It would be decided to      leave potentially mineralizable affected dentin by hand sensitivity. All the teeth would then temporarily sealed with glass ionomer cement and coating agent. After      4 months, radiographic and clinical examinations would be repeated. Following rubber dam      isolation and anesthesia, temporary fillings would be removed. Removing of Ca(OH)2 on the      remaining carious dentin would be carefully performed with excavators. Subsequent to this      procedure, remaining demineralized dentin would be completely removed in all groups. Floor of the      cavity would then be covered with Ca(OH)2 base material (Dycal; Dentsply/Caulk) and glass ionomer      lining. The cavities would then be restored with composite resin after the two-stages self-etch      bond application.&lt;/para&gt;&lt;para&gt;During the microbiological analysis, dentin samples would be collected with a sterile carbide bur #14 from      each group for microbiological analyses. Clinical photograph would be taken with dental explorers pointing to ensure that all samples would be      collected from the same site in all following stages. The dentine samples would be collected      enough to fill the slots of a sterile no.14 round carbide bur and the respective samples would be      placed into 1 ml thiogluconate medium then transported to the microbiology laboratory in 2      h to be analyzed for the mutans streptococci, lactobacilli and the total number of colony      forming units (CFU). The samples would be homogenized on a vortex mixer for 15 s under laboratory conditions.      Mitis Salivarius agar as the selective medium for Streptococcus mutans, rogosa agar for      Lactobacilli and Brain Hearth agar supplemented 5% blood for the total number of CFU would be      used. Tenfold dilution would be plated onto agars and incubated anaerobically for 48 h and      the colonies would be counted on the convenient dilution.      Clinical evaluation for the clinical analysis, the colour, consistency and humidity of the      dentine would also recorded during taking microbiological samples. Color findings classifications would be recorded according to following criteria: light yellow,      yellow, light brown, dark brown, black. Classification of dentin consistency would be determined      by probing and criteria were very soft, soft, moderate hard and hard. Dentin      humidity would be recorded as wet and dry. Accordingly, the dentine would be probed and if moisture      leakage occurred, it would be classified as wet or if it did not then it would be classified as      dry.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Turkey"><Sites><Site><Name>Izmir Katip Celebi University</Name><Address1>İzmir</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16681">Others</PatientSegment><SubSegments><SubSegment id="18747">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17380">Treatment Naive Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18265">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16572">Subjects with Dental Caries</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03737201</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other mouth disease" id="43598"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other mouth disease" id="33060"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="33061"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="34642"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="33062">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other mouth disease" id="35078"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="35331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="35327">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="27917"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="28183"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-07-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="361272"><TitleDisplay>Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure</TitleDisplay><TitleOfficial>A Phase III, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03750552</Identifier><Identifier type="Secondary Organisational">2018-003289-15</Identifier><Identifier type="Organisational Study">0169</Identifier></Identifiers><Indications><Indication id="1836">Orthostatic hypotension</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ampreloxetine</Name><Drug id="60758">ampreloxetine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="60758">ampreloxetine</Drug><IndicationsPioneer/><Companies><Company><Company id="1096800">Theravance Biopharma Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="60758" type="Drug"><TargetEntity id="696060" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1096800" type="Company"><TargetEntity id="5042372920" type="organizationId">Theravance Biopharma US Inc</TargetEntity></SourceEntity><SourceEntity id="1836" type="ciIndication"><TargetEntity id="I95.1" type="ICD10"/><TargetEntity id="10031127" type="MEDDRA"/><TargetEntity id="D007024" type="MeSH"/><TargetEntity id="-1552133736" type="omicsDisease"/><TargetEntity id="252" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>8</NumberOfSites><CompaniesSponsor><Company id="1096800">Theravance Biopharma Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="2658">Hypertensive</Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2946">Analgesic</Class><Class id="3">5-HT uptake inhibitor</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>188</PatientCountEnrollment><DateStart>2019-01-24T00:00:00Z</DateStart><DateEnd type="estimated">2020-09-01T00:00:00Z</DateEnd><DateChangeLast>2019-04-18T02:04:46Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>medinfo@theravance.com</Email><Name>Theravance Biopharma Call Center</Name><Phone>1-855-633-8479</Phone></Contact><Contact type="Scientific contact"><Affiliation>Theravance Biopharma</Affiliation><Name>Medical Monitor</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is male or female and at least 30 years old&lt;/li&gt;&lt;li&gt;Subject must meet the diagnostic criteria of snOH, as demonstrated by a &gt;/= 20 mm Hg (systolic) or &gt;/= 10 mm Hg (diastolic) within 3 min of being tilted-up to &gt;/= 60o from a supine position as determined by a tilt-table test&lt;/li&gt;&lt;li&gt;Subject must score at least a 4 on the Orthostatic Hypotension Symptom Assessment Question #1 at randomization visit&lt;/li&gt;&lt;li&gt;For subjects with PD only: Subject has a diagnosis of PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria (1992)&lt;/li&gt;&lt;li&gt;For subjects with MSA only: Subject has a diagnosis of possible or probable MSA of the Parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to The Gilman Criteria (2008)&lt;/li&gt;&lt;li&gt;For subjects with PAF only: Subject has impaired autonomic reflexes, as determined by absence of Phase IV BP overshoot after release of the Valsalva strain&lt;/li&gt;&lt;li&gt;Subject has plasma NE levels&amp;gt; 100 pg/ml after being in seated position for 30 min&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has a known systemic illness known to produce autonomic neuropathy, including but not limited to diabetes mellitus, diabetes insipidus, diabetic neuropathy, amyloidosis, and autoimmune neuropathies&lt;/li&gt;&lt;li&gt;Subject has a known intolerance to other NRIs or SNRIs&lt;/li&gt;&lt;li&gt;Subject currently uses concomitant antihypertensive medication for the treatment of essential hypertension unrelated to autonomic dysfunction&lt;/li&gt;&lt;li&gt;Subject has used strong CYP1A2 inhibitors or inducers within 7 days or five half-lives, whichever is longer, prior to randomization or requires concomitant use until the follow-up visit&lt;/li&gt;&lt;li&gt;Subject has changed dose, frequency, or type of prescribed medication for orthostatic hypotension (e.g., ephedrine, dihydroergotamine, or fludrocortisone), within 7 days prior to randomization visit. These medications must be tapered off postrandomization. Tapering will follow the product's United States (US) package insert. Midodrine and droxidopa must be tapered off at least 7 days prior to randomization&lt;/li&gt;&lt;li&gt;Subject has a known or suspected alcohol or substance abuse within the past 12 months (DSM-IV-TR definition of alcohol or substance abuse)&lt;/li&gt;&lt;li&gt;Subject has a clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months&lt;/li&gt;&lt;li&gt;Subject has used any monoamine oxidase inhibitor (MAO-I) within 14 days prior to randomization&lt;/li&gt;&lt;li&gt;Subject has a history of untreated closed angle glaucoma, or treated closed angle glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk to the subject&lt;/li&gt;&lt;li&gt;Subject has any significant uncontrolled cardiac arrhythmia&lt;/li&gt;&lt;li&gt;Subject has a Montreal Cognitive Assessment (MoCA)&amp;lt;/= 23&lt;/li&gt;&lt;li&gt;Subject had a myocardial infarction in the past 6 months or has current unstable angina&lt;/li&gt;&lt;li&gt;Subject has known congestive heart failure (New York Heart Association [NYHA] Class 3 or 4)&lt;/li&gt;&lt;li&gt;Subject has a clinically significant abnormal laboratory findings (eg, alanine aminotransferase [ALT] or aspartate aminotransferase [AST]&amp;gt; 3.0 x upper limit of normal [ULN]; blood bilirubin [total]&amp;gt; 1.5 x ULN; estimated glomerular filtration rate (eGFR) &amp;lt; 30 ml/min/1.73m(2), or any abnormal laboratory value that could interfere with safety of the subject)&lt;/li&gt;&lt;li&gt;Subject has demonstrated a history of lifetime suicidal ideation and/or suicidal behavior, as outlined by the C-SSRS (Baseline/Screening Version) subject should be assessed by the rater for risk of suicide and the subject's appropriateness for inclusion in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change from baseline in OHSA#1 at week 4: score change from baseline on Question 1 of the Orthostatic Hypotension Symptom Assessment (OHSA ). Question #1 assesses dizziness, lightheadedness, feeling faint, or feeling like you might blackout</Description><Timeframe>Baseline to Week 4</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from baseline in COMPASS-31 at week 4: Composite Autonomic Symptoms Score-31 (COMPASS-31) is an assessment that provides a quantitative measure of autonomic symptoms. Outcome measure only applies to subjects with Multiple System Atrophy (MSA)</Description><Timeframe>Baseline to Week 4</Timeframe></Measure><Measure><Description>Change from baseline in OHDAS composite score in Weeks 1 to 4 Orthostatic Hypotension Daily Activities Scale (OHDAS ) is an assessment of how low blood pressure symptoms affect daily life: OHDAS is a 4 item assessment that uses an 11 point scale from 0 to 10, with 0 indicating no symptoms/no interference and 10 indicating the worst possible symptoms/complete interference</Description><Timeframe>Baseline, week 1, 2, 3, 4</Timeframe></Measure><Measure><Description>Change from baseline in OHSA composite score in weeks 1 to 4: Orthostatic Hypotension Symptom Assessment (OHSA ) is an assessment of the severity of symptoms from low blood pressure</Description><Timeframe>Baseline, week 1, 2, 3, 4</Timeframe></Measure><Measure><Description>Change from baseline in PDQ-8 at Week 4: Parkinson's Disease Questionnaire-8 (PDQ-8) is an assessment for Parkinson's Disease (PD) subjects. Outcome measure only applies to subjects with PD</Description><Timeframe>Baseline to week 4</Timeframe></Measure><Measure><Description>Change from baseline in UMSARS at Week 4: Unified Multiple System Atrophy Rating Scale (UMSARS) is an assessment for Multiple System Atrophy (MSA) subjects. Outcome measure only applies to subjects with MSA</Description><Timeframe>Baseline to week 4</Timeframe></Measure><Measure><Description>Change from baseline in UPDRS at Week 4 Unified Parkinson's Disease Rating Scale (UPDRS) is a clinical rating scale for Parkinson's Disease (PD). Outcome measure only applies to subjects with PD: UPDRS is made up of 6 parts. Only parts 2 &amp; 3 (self evaluation of daily activities &amp; clinician scored motor evaluation) will be measured at Week 4</Description><Timeframe>Baseline to week 4</Timeframe></Measure><Measure><Description>Incidence of falls: incidence of patient-reported falls</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>PGI-C at Week 4 Using the Patient Global Impression of Change (PGI-C) scale, a subject rates their total improvement compared to baseline: PGI-C uses a 7 point scale ranging from 1 (very much improved) to 7 (very much worse)</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>Standing systolic blood pressure during orthostatic standing test: systolic blood pressure taken during the standing portion of the orthostatic standing test</Description><Timeframe>Baseline, week 1, 2, 3, 4</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a registrational phase III, 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study study to evaluate efficacy, safety, and tolerability of &lt;ulink linkType="Drug" linkID="60758"&gt;TD-9855&lt;/ulink&gt; in subjects with      primary autonomic failures (multiple system atrophy[MSA], Parkinsons disease[PD], or Pure autonomic failure [PAF]) and Symptomatic Neurogenic Orthostatic Hypotension (snOH)  [&lt;ulink linkType="Reference" linkID="2114319"&gt;2114319&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019, first patient was dosed [&lt;ulink linkType="Reference" linkID="2114319"&gt;2114319&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists of three periods: &lt;br/&gt;2-week screening.&lt;br/&gt;4-week randomized treatment.&lt;br/&gt;2-week follow up.&lt;/para&gt;&lt;para&gt;The study involes two experimental arms:&lt;br/&gt;Arm 1: participants would  receive a single, 10 mg, po daily dose of TD-9855 for 4 weeks.&lt;br/&gt;Arm 2:  participants randomized to placebo would receive a single, oral, daily dose of placebo for 4 weeks  [&lt;ulink linkType="Reference" linkID="2114319"&gt;2114319&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Collaborative Neuroscience Network, LLC</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90806</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Colorado Springs Neurological Associates, PC</Name><Address1>Colorado Springs</Address1><Address2>Colorado</Address2><Address3>80907</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Inland Northwest Research</Name><Address1>Spokane</Address1><Address2>Washington</Address2><Address3>99202</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Neurostudies, Inc</Name><Address1>Port Charlotte</Address1><Address2>Florida</Address2><Address3>33952</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>New York University Langone Health</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Parkinson's Disease and Movement Disorders Center</Name><Address1>Boca Raton</Address1><Address2>Florida</Address2><Address3>33486</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>University of Texas Southwestern Medical Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75390</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Wake Forest University Baptist Health Sciences</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27157</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other cardiovascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18214">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16193">Subjects with Hypotension</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="20100">Subjects with Symptomatic Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15996">Subjects with Neurodegenerative Disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03750552</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2018-003289-15</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Parkinsons disease" id="29335"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="43088"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="43649"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="44220"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Parkinsons disease" id="44805"><Endpoint>Neurological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Parkinsons disease" id="44895"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Parkinsons disease" id="10178"><Endpoint>Assessment of Non-Motor Symptoms of Parkinson's Disease</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="10181">Assessment of autonomic dysfunction</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10184"><Endpoint>Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10200"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10201"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="29335"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="29292">Parkinson's Disease Questionnaire (PDQ-8)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43088"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43365"><Endpoint>Assessment of Morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43436"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43505"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Other cardiovascular disease" id="43507">Blood pressure assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43649"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43840"><Endpoint>Assessment of Morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="44220"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="44805"><Endpoint>Neurological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="44895"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="45172"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Parkinsons disease" id="10217"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="42861"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Other neurological disease" id="42924"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Parkinsons disease" id="6061"><Criterion>Subjects with Diagnosis of Parkinson's Disease by Clinical Criteria</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6063">Subjects diagnosed by UK Parkinson's Disease Society (UKPDS) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6068"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6079">Subjects with autonomic dysfunction</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6150"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="32471"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="33014">Subjects co-morbid with hypotension</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33372"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="34796"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="35439"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Parkinsons disease" id="7726"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="7728"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="7734"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="7746"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="7759"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7763">Subjects with history of Monoamine Oxidase inhibitors (MAOi) therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Parkinsons disease" id="7769"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7772">Subjects with history of antihypertensive therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Parkinsons disease" id="7786"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="23705"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24094"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24155"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24386"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24402"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24585"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="24901"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25146"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="24456">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="25807"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25811"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="26002"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="26092"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="26330"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7743">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Parkinsons disease" id="7744">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Parkinsons disease" id="26517"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="26572"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24396">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="26702"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24385">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="27233"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27423"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="27436"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="27446"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27740"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29170"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="29348"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7794">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="29932"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-09-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-20T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-01-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-01-10T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="3641"><TitleDisplay>Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD</TitleDisplay><TitleOfficial>A 48-Week, Double-Blind, Double-Dummy, Randomized, Multinational, Multicenter, Three-arm Parallel-Group Clinical Study of Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant Versus Fixed Combination Budesonide Plus Formoterol DPI Versus Formoterol DPI in Patients With Stable Severe Chronic Obstructive Pulmonary Disease (COPD)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">DM/PR/033011/005/05</Identifier><Identifier type="NCT">NCT00476099</Identifier><Identifier type="Other">2006-002489-20</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1905" role="Therapeutic effect marker" type="Physiological">Peak expiratory flow rate</BiomarkerName><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2029" role="Therapeutic effect marker" type="Physiological">Forced expiratory flow </BiomarkerName><BiomarkerName id="2098" role="Therapeutic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>beclometasone dipropionate + formoterol fumarate (inhaled, Modulite), Chiesi</Name><Drug id="57106">beclometasone dipropionate + formoterol fumarate (inhaled, Modulite), Chiesi</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>budesonide + formoterol fumarate, AstraZeneca</Name><Drug id="30712">budesonide + formoterol fumarate, AstraZeneca</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>formoterol</Name><Drug id="6140">formoterol</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="57106">beclometasone dipropionate + formoterol fumarate (inhaled, Modulite), Chiesi</Drug><IndicationsPioneer><Indication id="1185">Chronic obstructive pulmonary disease</Indication></IndicationsPioneer><Companies><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="57106" type="Drug"><TargetEntity id="359802" type="siDrug">Beclomethasone dipropionate/formoterol fumarate</TargetEntity></SourceEntity><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="2954">Steroidal anti-inflammatory</Class><Class id="3189">Corticosteroid agonist</Class><Class id="646">Bronchodilator</Class></Class><Technologies><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="753">Microparticle formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="618">Powder formulation inhalant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>828</PatientCountEnrollment><PatientCountEvaluable>718</PatientCountEvaluable><DateStart>2006-12-31T00:00:00Z</DateStart><DateChangeLast>2019-03-07T02:03:41Z</DateChangeLast><DateAdded>2007-08-09T15:28:04Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Department of Medicine, Clinical Sciences Center University Hospital Aintree, Liverpool, United Kingdom</Affiliation><Name>Peter Calverley</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Clinical diagnosis of COPD (according to GOLD guidelines)&lt;/li&gt;&lt;li&gt;Male and female outpatients, aged &gt;/=  40 years&lt;/li&gt;&lt;li&gt;Forced expiratory volume in 1 second (FEV1) &gt;/= 30% and&amp;lt; 50% of predicted normal post-bronchodilator (and at least 0.7 L absolute value)&lt;/li&gt;&lt;li&gt;FEV1/FVC ratio&amp;lt;/=  70%&lt;/li&gt;&lt;li&gt;COPD symptoms for at least two years&lt;/li&gt;&lt;li&gt;At least one  exacerbation requiring medical intervention (oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 2 to 12 months before screening&lt;/li&gt;&lt;li&gt;Current or previous smoker with a cumulative exposure to smoke of more than 20-pack year&lt;/li&gt;&lt;li&gt;Written informed consent obtained&lt;/li&gt;&lt;li&gt;A cooperative attitude and ability to be trained to use correctly the pMDI and the DPI inhalers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Female subjects: pregnant, lactating mother or lack of efficient contraception in a subject with child-bearing potential (ie, contraceptive methods other than oral contraceptives, IUD, tubal ligature)&lt;/li&gt;&lt;li&gt;Current or past diagnosis of asthma&lt;/li&gt;&lt;li&gt;History of allergic rhinitis or other atopic disease (eg, eczema)&lt;/li&gt;&lt;li&gt;Onset of obstructive symptoms early in life (for example childhood)&lt;/li&gt;&lt;li&gt;Variability of symptoms from day to day and frequent symptoms at night and early morning (suggestive of asthma)&lt;/li&gt;&lt;li&gt;Positive FEV1 reversibility test: ∆FEV1 30 min following inhalation of 200 microg of salbutamol pMDI more than 12% of predicted normal value [FEV1 change (L)/FEV1 predicted normal value (L) x 100]&lt;/li&gt;&lt;li&gt;A total blood eosinophil count higher than 500/microl&lt;/li&gt;&lt;li&gt;Clinically significant or unstable concurrent disease: eg, uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; significant pulmonary disease (eg, tuberculosis, lung cancer or other); cardiovascular disease (eg, coronary artery disease, uncontrolled hypertension); gastrointestinal disease (eg, active peptic ulcer); neurological disease; haematological disease; autoimmune disorders, or other&lt;/li&gt;&lt;li&gt;Evidence of heart failure (NYHA class III-IV)&lt;/li&gt;&lt;li&gt;Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease.&lt;/li&gt;&lt;li&gt;Patients with serum potassium levels ≤ 3.5 mEq/L (or 3.5 mmol/L)&lt;/li&gt;&lt;li&gt;Patient with narrow-angle glaucoma&lt;/li&gt;&lt;li&gt;QTc interval (Bazett’s formula) higher than 450 msec at screening visit (Visit 1)&lt;/li&gt;&lt;li&gt;Lower respiratory tract infection within two months before screening visit (Visit 1) and during the run-in period of the study&lt;/li&gt;&lt;li&gt;Hospitalisation or emergency room treatment for an acute COPD exacerbation in the two months before screening visit (Visit 1) and during the run-in period of the study&lt;/li&gt;&lt;li&gt;Long term oxygen therapy&lt;/li&gt;&lt;li&gt;Patients treated with oral or injectable corticosteroids and antibiotics for a COPD exacerbation and/or a lower respiratory tract infection in the two months preceding the screening visit (Visit 1) and during the run-in period of the study&lt;/li&gt;&lt;li&gt;Patients treated with depot corticosteroids in the two months preceding the screening visit (Visit 1) and during the run-in period of the study&lt;/li&gt;&lt;li&gt;Changes in dose, schedule, formulation or product of a nasal corticosteroid or an oral modified-release theophylline within two months of screening visit (Visit 1) and during the run-in period of the study&lt;/li&gt;&lt;li&gt;Patients treated with long-acting antihistamines (eg, astemizole, terfenadine) in the two months preceding the screening visit (Visit 1) and during the 52-week study period&lt;/li&gt;&lt;li&gt;Patients treated with beta-blockers in the week preceding the screening visit (Visit 1) and during the 52-week study period&lt;/li&gt;&lt;li&gt;Patients with allergy, sensitivity or intolerance to sympathomimetic drugs or corticosteroids or to any of the excipients contained in the study drugs&lt;/li&gt;&lt;li&gt;Patients who have evidence of alcohol or drug abuse, not compliant with the study protocol or not compliant with the study treatments&lt;/li&gt;&lt;li&gt;Participation in another clinical trial with an investigational drug in the four weeks preceding the screening visit (Visit 1)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of COPD exacerbations and pre-dose morning FEV1</Description><Timeframe>One year treatment,  from baseline to 48 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Other pulmonary function parameters,</Description><Timeframe>One year treatment</Timeframe></Measure><Measure><Description>COPD symptom scores and Quality of Life</Description><Timeframe>One year treatment</Timeframe></Measure><Measure><Description>Safety and tolerability</Description><Timeframe>One year treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study was to evaluate the one-year efficacy and safety of the fixed combination &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol&lt;/ulink&gt; pMDI  bid regimen in patients with stable severe chronic obstructive pulmonary disease (COPD).&lt;/para&gt;&lt;para&gt;Secondary objective:&lt;br/&gt;To assess the efficacy of the test treatment in terms of health related quality of life (HRQL), COPD symptoms, other pulmonary function parameters (FVC, PEF, FEF25-75%), use of 'rescue' medication, number of moderate and severe COPD exacerbations, time to first moderate and severe COPD exacerbation, dyspnoea index, BODE index, and to evaluate the safety profile through adverse events (AEs) and adverse drug reactions (ADRs) reporting, electrocardiography, blood chemistry (serum potassium, serum cortisol and plasma glucose levels), vital signs.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in December 2010. Improvement in pre-dose morning FEV1 was 0.077, 0.080  and 0.026 l in patients treated with &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="30712"&gt;budesonide + formoterol&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6140"&gt;formoterol&lt;/ulink&gt; respectively. Treatment with &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol&lt;/ulink&gt; was not inferior to &lt;ulink linkType="Drug" linkID="30712"&gt;budesonide + formoterol&lt;/ulink&gt; and superior to &lt;ulink linkType="Drug" linkID="6140"&gt;formoterol&lt;/ulink&gt; (p = 0.046). The overall rate of COPD exacerbations/patient/year was similar and not statistically significantly different among treatments (0.414, 0.423 and 0.431, respectively). Quality of life and COPD symptoms improved in all groups and use of rescue medication decreased.  &lt;ulink linkType="Drug" linkID="57106"&gt;Beclomethasone dipropionate + formoterol&lt;/ulink&gt;  was safe and well-tolerated in patients with severe stable COPD [&lt;ulink linkType="Reference" linkID="1156865"&gt;1156865&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The purpose of this study was to evaluate the long-term efficacy and safety of the fixed combination &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol&lt;/ulink&gt; pressurized metered dose inhaler (pMDI) bid regimen in patients with stable severe COPD. Patients were randomized to receive either &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol &lt;/ulink&gt;  (100 microg + 6 microg, two puffs via oral inhalation ) or &lt;ulink linkType="Drug" linkID="30712"&gt;budesonide + formoterol&lt;/ulink&gt; (200 microg + 6 microg, two oral inhalations) dry powder inhalers (DPI) or &lt;ulink linkType="Drug" linkID="6140"&gt;formoterol&lt;/ulink&gt; (12 microg, one oral inhalation ) DPI, bid at 8.00 a.m. and 8.00 p.m during 48 weeks of treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive &lt;ulink linkType="Drug" linkID="57106"&gt;beclomethasone dipropionate + formoterol&lt;/ulink&gt; (200/12 microg pressurized metered dose inhaler), &lt;ulink linkType="Drug" linkID="30712"&gt;budesonide + formoterol&lt;/ulink&gt; (400/12 microg dry powder inhaler) or &lt;ulink linkType="Drug" linkID="6140"&gt;formoterol&lt;/ulink&gt; (12 microg dry powder inhaler) bid for 48 weeks [&lt;ulink linkType="Reference" linkID="1156865"&gt;1156865&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="1354">formoterol</Intervention><Treatments><Treatment><Dose>12 microgram</Dose><Route>Inhalant</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Thomas Similowski</Name><Address1>Paris</Address1><Address3>75000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="557">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="559">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="3736">Smokers</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="562">Subjects with GOLD Stage 3/Severe COPD</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="564">Subjects with disease related complications</PatientSegment><SubSegments><SubSegment id="565">Subjects with acute exacerbation of COPD/Infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00476099</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2006-002489-20</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4473"><Endpoint>Assessment of Exacerbations</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4474">Assessment of exacerbation rate/frequency/number</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4567"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4418"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4422">Severity of symptoms/symptom scores (SS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="30222">Assessment of quality of life</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4483"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4604"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2063">Subjects with symptomatic COPD</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2099"><Criterion>Subjects with Exacerbations</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2101">Subjects with 1 exacerbation within the past 1 year</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="2105">Subjects with severe exacerbation requiring hospitalization</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="33821"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="4301">Current smokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4302">Non smokers/exsmokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4306">Subjects with smoking history of &gt;= 20 pack years</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="34771"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2067">Subjects with GOLD Stage 3/Severe COPD</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3044"><Criterion>Subjects with Specific Stage/Type of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="3046">Subjects with acute exacerbation of COPD</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3058"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3151"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="20267">Subjects with history of/scheduled for supplemental oxygen use</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="20269">Subjects with history of/scheduled for COPD drug therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3194"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3230"><Criterion>Subjects with Positive Bronchodilator Reversibility Test</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-05-18T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-08-09T15:28:04Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2018-02-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="85408"><TitleDisplay>Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma</TitleDisplay><TitleOfficial>A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">R-07-214</Identifier><Identifier type="NCT">NCT01545427</Identifier><Identifier type="Secondary Organisational">#031-06</Identifier></Identifiers><Indications><Indication id="1105">Scleroderma</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="130" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 2</BiomarkerName><BiomarkerName id="173" role="Therapeutic effect marker" type="Genomic;Proteomic">Matrix metalloproteinase-9</BiomarkerName><BiomarkerName id="174" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-12</BiomarkerName><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="199" role="Therapeutic effect marker" type="Genomic;Proteomic">Vascular cell adhesion protein 1</BiomarkerName><BiomarkerName id="249" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-13</BiomarkerName><BiomarkerName id="252" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferon gamma</BiomarkerName><BiomarkerName id="316" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-4</BiomarkerName><BiomarkerName id="319" role="Therapeutic effect marker" type="Genomic;Proteomic">Transforming growth factor beta 1</BiomarkerName><BiomarkerName id="367" role="Therapeutic effect marker" type="Genomic;Proteomic">Intercellular adhesion molecule-1</BiomarkerName><BiomarkerName id="369" role="Therapeutic effect marker" type="Genomic;Proteomic">E-selectin</BiomarkerName><BiomarkerName id="383" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-17A</BiomarkerName><BiomarkerName id="411" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 5</BiomarkerName><BiomarkerName id="477" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 4</BiomarkerName><BiomarkerName id="543" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 3</BiomarkerName><BiomarkerName id="556" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-1 alpha</BiomarkerName><BiomarkerName id="2125" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor receptor superfamily member 5</BiomarkerName><BiomarkerName id="2331" role="Therapeutic effect marker" type="Proteomic">VEGF/SEMA ratio</BiomarkerName><BiomarkerName id="2419" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 7</BiomarkerName><BiomarkerName id="10136" role="Therapeutic effect marker" type="Genomic;Proteomic">Platelet-derived growth factor</BiomarkerName><BiomarkerName id="36044" role="Therapeutic effect marker" type="Proteomic">Endothelins</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>imatinib</Name><Drug id="11460">imatinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11460">imatinib</Drug><IndicationsPioneer/><Companies><Company><Company id="1043527">Lawson Health Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="11460" type="Drug"><TargetEntity id="229058" type="siDrug">Imatinib mesylate</TargetEntity></SourceEntity><SourceEntity id="1043527" type="Company"><TargetEntity id="4297906117" type="organizationId">Lawson Health Research Institute</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1105" type="ciIndication"><TargetEntity id="10039710" type="MEDDRA"/><TargetEntity id="732" type="siCondition"/></SourceEntity><SourceEntity id="3524" type="Action"><TargetEntity id="1630" type="Mechanism">Abl Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2a Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Safety Issues</Reason></ReasonForTrialDiscontinuation><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043527">Lawson Health Research Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23137">Novartis AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="13571">Bcr protein inhibitor</Action><Action id="3524">Abl tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="7025">Signal transduction inhibitor</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="664">Fibrosuppressant</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2008-04-30T00:00:00Z</DateStart><DateEnd type="actual">2008-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:39:32Z</DateChangeLast><DateAdded>2012-03-08T04:26:41Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Lawson Health Research Institute, Western University</Affiliation><Name>Janet E Pope, MD MPH FRCPC</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;  Subjects must be able to give informed consent&lt;/li&gt;&lt;li&gt;Subjects must meet preliminary criteria for scleroderma&lt;/li&gt;&lt;li&gt;Subjects must have diffuse skin involvement&lt;/li&gt;&lt;li&gt;Disease must appear to be active as measured by worsening skin score    and/or             increased ESR&lt;/li&gt;&lt;li&gt;Serum serum glutamic oxaloacetic transaminase (SGOT)&amp;lt; 1.5 x upper limit of normal.&lt;/li&gt;&lt;li&gt;Bilirubin&amp;lt; 1.5 x upper limit of normal&lt;/li&gt;&lt;li&gt;AST/ALT&amp;lt; 2.5 x upper limit of normal&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any past exposure to&lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Women of child bearing potential must be practicing an acceptable form of             contraception (oral contraceptive pill [OCP], depo-provera, intra-uterine device [IUD], condoms with spermicidal or sterilization of             subject or partner)&lt;/li&gt;&lt;li&gt;Women who are breastfeeding&lt;/li&gt;&lt;li&gt;Men whose partners could conceive must be practicing acceptable contraception -Certain abnormal labs including:  neutrophil count&amp;lt; 1.5 x 10(9)/l, platelets &amp;lt; 50 x 10(9)/l&lt;/li&gt;&lt;li&gt;Serious comorbidity that may impair the ability to complete the study (such as severe             heart disease, severe pulmonary hypertension) and other comorbidities&lt;/li&gt;&lt;li&gt;Prednisone at doses of&amp;gt; 10 mg qd&lt;/li&gt;&lt;li&gt;Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and             methotrexate&lt;/li&gt;&lt;li&gt;Serious liver disease&lt;/li&gt;&lt;li&gt;Creatinine&amp;gt; 200&lt;/li&gt;&lt;li&gt;Excluded:  ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin             nefazodone, pimozide, propafenone, quinidine, sibutramine and sildenafil where drug             interactions could occur&lt;/li&gt;&lt;li&gt;Subjects taking endothelin receptor blockers such as bosentan and sitaxsentan&lt;/li&gt;&lt;li&gt;  Alcohol consumption of&amp;gt; 3 drinks per week&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes in the levels of fibrotic and inflammatory biomarkers in skin biopsies and plasma samples: 26 fibrotic and inflammatory biomarkers were measured: PDGF-AA, PDGF-AB/BB, IL-13, IL-17, VEGF, TGF-beta1,soluble VCAM-1 (sVCAM-1), sICAM-1, sE-selectin, matrix metalloproteinase (MMP)-9, total plasminogen activator inhibitor (tPAI)-1, IL-1 alpha, IL-1 beta, IL-4, IL-6, IL-10, IL-12p70, IL-13, TNF- alpha, sCD40 ligand (sCD40L), IFN- gamma, monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta and chemokine ligand 5 (CCL5, also known as  RANTES [regulated on activation, normalT-cell expressed and secreted])</Description><Timeframe>Plasma samples were taken at baseline (0), 3 and 6 months (study end) and tissue biopsies were taken at baseline and 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The MRSS is a validated outcome measurement and is the usual primary outcome measurement for all trials of disease modification in scleroderma.  It is positively correlated with internal organ involvement and has been shown to improve or worsen in many patients</Description><Timeframe>Baseline, 3 months and 6 months (study end)</Timeframe></Measure><Measure><Description>This study will use the CTCAE (NCI Common Terminology Criteria for Adverse Events) versions 3.0 for toxicity and adverse event reporting. If multiple dose-reducing toxicities are present, the greatest dose reduction schedule should be used. Information about all adverse events will be collected and recorded on the AE case report form and followed as appropriate. SAEss occurring &gt; 4 weeks after study discontinuation need only be reported if a relationship to the study drug (or therapy) is suspected</Description><Timeframe>From treatment start until 4 weeks after after the patient has stopped study participation</Timeframe></Measure><Measure><Description>HAQ</Description><Timeframe>Baseline, 3 months and 6 months (study end)</Timeframe></Measure><Measure><Description>Patient global assessment: patient assessment of global disease activity on a 100 mm VAS</Description><Timeframe>Baseline, 3 months and 6 months (study end)</Timeframe></Measure><Measure><Description>Physician global assessment: physician global assessment of disease activity on a 100 mm VAS</Description><Timeframe>Baseline, 3 months and 6 months (study end) VAS</Timeframe></Measure><Measure><Description>The SF36 health survey</Description><Timeframe>Baseline and 6 months</Timeframe></Measure><Measure><Description>Health transitiion score: 'compared to 6 months ago, how do you rate your health overall?:  much worse, worse, same, better, much better'</Description><Timeframe>Baseline and 6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  randomized, double blind,      placebo-controlled study was to investigate the effectiveness and safety of the drug &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt;      (imatinib) as a new treatment for patients with active diffuse scleroderma. &lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with active diffuse scleroderma would be enrolled after consenting and would receive      &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; (400 mg  qd or 200 mg bid) or  placebo.  Serum and skin biopsies would be collected for biomarkers.      Serum samples would be taken at baseline, 3 and 6 months and analyzed by ELISA/multiplexing      for changes in profibrotic cytokines including PDGF, VEGF, endothelin and TGF-beta.  Skin      biopsies would be taken prior to the first dose and at 6 months.  Modified Rodnan skin score      (MRSS), health assessment questionnaire (HAQ), MD (physician) and patient global assessments (100 mm visual analog scale [VAS]) would also      be done at times 0, 3, and 6 months.  Short form (SF)36 and health transition score would be done at 0 and      6 months.  Biochemistry for safety and inflammation would be done once a month for the      duration of the trial.&lt;br/&gt;&lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; at 400 mg  qd or placebo would be given po with food and a large glass of water      for 6 months.  As this is a proof of concept and phase IIa trial,  patients would be randomized      into active versus placebo groups in a 4 : 1 ratio, where n = 20.  Therefore, 16 patients would      receive active drug and 4 would receive placebo.&lt;/para&gt;&lt;para&gt;The specific aims would be:&lt;br/&gt;Primary outcome measurement: changes in cytokine expression in skin biopsies and serum           samples for profibrotic cytokines.&lt;br/&gt;To determine the between groups differences from baseline to final skin score on           &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; and placebo at 6 months using   MRSS.&lt;br/&gt;To compare the AEs (adverse events) and SAEs (serious adverse events) between the           groups.&lt;/para&gt;&lt;para&gt;The secondary objectives would be:&lt;br/&gt;Comparing secondary outcome measurements such as:  MD global, patient global, HAQ, SF36,      health transition, erythrocyte sedmentation rate (ESR), C-reactive protein (CRP).&lt;/para&gt;&lt;para&gt;Randomization and blinding:&lt;br/&gt;The randomization would be stratified by current use of methotrexate.  It was anticipated that      the majority of patients in this trial would not be taking methotrexate at time of      randomization, but stratification should balance the groups if there was a heterogenous      response.  The randomization would be done in balanced blocks of five, after stratification by      methotrexate use.  The pharmacy would be called and would provide the medication and would have      the randomization code.  The trial was double-blinded.&lt;/para&gt;&lt;para&gt;Concomitant medications:&lt;br/&gt;Stable dose concomitant methotrexate of up to 25 mg/week if tolerated (po or sc) could be      continued throughout the study.  In addition, if necessary, folate could be added or increased      to decrease side effects.&lt;br/&gt;All standard of care was allowed except for the medications listed above.  Thus treatment for      gastroesophageal reflux disease (GERD), Raynaud's, digital ulcers, hypertension (HTN), delayed gastrointestinal (GI) emptying, small bowel overgrowth, Sjogren's      symptoms, arthritis (using NSAIDs or low dose prednisone) was allowed.  Severe pulmonary arterial hypertension (PAH) and severe      interstitial lung disease (ILD) was excluded as there could be expectations that this comorbidity may interfere with the      current 24-week treatment protocol.  Steroids could be increased in the rare chance that a      patient develops a complication or co-morbidity that requires higher doses of steroids as      part of standard care.  Regular need for antibiotics for small bowel overgrowth was allowed.&lt;/para&gt;&lt;para&gt;Good clinical practice would be followed and other appropriate treatment would not be denied.      This is an 'add-on' treatment to standard care. Concomitant medications would be assumed to      be held stable throughout the study.  Patients taking any medications that might interact with      &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; (eg, selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCA], &lt;ulink linkType="Drug" linkID="48629"&gt;trazodone&lt;/ulink&gt;, benzodiazepines, betablockers, etc) would be monitored      cautiously.&lt;/para&gt;&lt;para&gt;Since &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; had been postulated (by a case report) to improve PAH annual echocardiograms that were done as part of standard care might be      compared between the groups determining the estimated pulmonary arterial pressure (PAP) on echocardiogram.&lt;/para&gt;&lt;para&gt;AEs and SAEs:&lt;br/&gt;The University of Western Ontario (UWO) ethics  committee would approve the protocol and any      amendments and would be informed of any SAEs as per usual research conduct.  The patients were      free to withdraw consent or drop out at any time with no adverse effect on their future      care.  As per any trial, AEs and SAEs would be collected.  SAEs would be reported in an      expedited way to the UWO ethics committee and &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Pregnancies:&lt;br/&gt;Pregnancy or fathering of a child, although not itself a SAE should also      be reported on a SAE form or pregnancy form and be followed up to      determine outcome, including spontaneous or voluntary termination, details of birth, and the      presence or absence of any birth defects or congenital abnormalities.  In addition to any      pregnancy or fathering of a child within 84 days (12 weeks or 3 months) after the last      &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; intake had to be reported and recorded as an SAE.&lt;/para&gt;&lt;para&gt;Any pregnancy that occurs during study participation should be reported using a clinical      trial pregnancy form. To ensure patient safety each pregnancy must also be reported to      &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt; within 24 h of learning of its occurrence. The pregnancy should be followed up      to determine outcome, including spontaneous or voluntary termination, details of birth, and      the presence or absence of any birth defects or congenital abnormalities or maternal and      newborn complications.&lt;br/&gt;Patients would be informed of the risks involved in becoming pregnant while taking &lt;ulink linkType="Drug" linkID="11460"&gt;Gleevec&lt;/ulink&gt; in      the letter of information and female partners of male patients  would be required to      read and sign a 'pregnant partner data release form' acknowledging that they had been      informed of these risks as well.&lt;/para&gt;&lt;para&gt;Discontinuation of treatment:&lt;br/&gt;The patients were free to drop out at any time.  A severe allergic reaction would necessitate      withdrawal.  If there were sustained cytopenias (WBC &amp;lt; 2.0,  hemoglobin &amp;lt; 8.0 or platelet &amp;lt; 50,000) for two      infusions in a row then the patient would be withdrawn.  If there was a WBC &amp;lt; 1.0 or hemoglobin &amp;lt; 7.5      or platelet &amp;lt; 10,000 at any time, the patient would be withdrawn.  If there were sustained      elevations of AST/ALT twice in a row, of twice the upper limit of normal, then the      methotrexate would be decreased by 5 mg/week.  If the elevation persists for two more tests,      the methotrexate would be held for 2 weeks and the liver enzymes repeated.  If still      elevated, the methotrexate would be cut in half and if still elevated and no other      concomitant meds were thought to be causing the elevation, then the patient would  be      withdrawn.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;Frequent adverse events occurred early in treatment with poor tolerability.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Lawson Health Research Institute</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 4V2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01545427</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2008-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-03-01T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-03-08T04:26:41Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="94787"><TitleDisplay>Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer</TitleDisplay><TitleOfficial>Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-resistant, Metastatic Prostate Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CO11816</Identifier><Identifier type="NCT">NCT01706458</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName><BiomarkerName id="64" role="Therapeutic effect marker" type="Cellular">Circulating Tumor Cells</BiomarkerName><BiomarkerName id="446" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostatic acid phosphatase</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>MVI-816</Name><Drug id="57199">MVI-816</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sipuleucel-T</Name><Drug id="17735">sipuleucel-T</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>sipuleucel-T</Name><Drug id="17735">sipuleucel-T</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17735">sipuleucel-T</Drug><IndicationsPioneer/><Companies><Company><Company id="13709">Dendreon Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="DOL1000742">University of Wisconsin-Madison</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="57199">MVI-816</Drug><IndicationsPioneer><Indication id="1069">Metastasis</Indication></IndicationsPioneer><Companies><Company><Company id="13709">Dendreon Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="DOL1000742">University of Wisconsin-Madison</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17735" type="Drug"><TargetEntity id="259673" type="siDrug">Sipuleucel-T</TargetEntity></SourceEntity><SourceEntity id="57199" type="Drug"><TargetEntity id="361719" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="13709" type="Company"><TargetEntity id="4295915801" type="organizationId">Dendreon Corp</TargetEntity></SourceEntity><SourceEntity id="DOL1000742" type="Company"><TargetEntity id="5000726299" type="organizationId">University of Wisconsin-Madison</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"/><TargetEntity id="D009362" type="MeSH"/><TargetEntity id="-1423187778" type="omicsDisease"/><TargetEntity id="618" type="siCondition"/></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"/><TargetEntity id="D000230" type="MeSH"/><TargetEntity id="-1620546969" type="omicsDisease"/><TargetEntity id="656" type="siCondition"/></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000742">University of Wisconsin-Madison</Company></CompaniesSponsor><CompaniesCollaborator><Company id="13709">Dendreon Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="37525">PSAP gene modulator</Action><Action id="9773">Prostatic acid phosphatase modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="12379">Therapeutic vaccine</Class><Class id="1545">Anticancer</Class><Class id="1879">DNA vaccine</Class><Class id="4790">Genetically engineered autologous cell therapy</Class></Class><Technologies><Technology id="67">Antigen</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="570">Cell therapy</Technology><Technology id="740">Infusion</Technology><Technology id="851">Intradermal formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="1653">Tumor antigen</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category><Category>Cell therapy</Category><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>18</PatientCountEnrollment><PatientCountEvaluable>18</PatientCountEvaluable><DateStart>2013-05-20T00:00:00Z</DateStart><DateEnd type="estimated">2021-06-12T00:00:00Z</DateEnd><DateChangeLast>2019-05-23T02:05:12Z</DateChangeLast><DateAdded>2012-10-17T10:06:01Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Wisconsin, Madison</Affiliation><Name>Douglas McNeel, M.D., PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)&lt;/li&gt;&lt;li&gt;Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (computed tomography [CT] of abdomen/pelvis, bone scintigraphy)&lt;/li&gt;&lt;li&gt;Castrate-resistant disease, defined as follows:&lt;ul&gt;&lt;li&gt;All patients must have received standard of care androgen deprivation treatment before trial entry (surgical castration versus gonadotropin-releasing hormone [GnRH] analogue or antagonist treatment), and patients receiving GnRH analogue or antagonist must continue this treatment throughout the time on this study&lt;/li&gt;&lt;li&gt;Patients may have been treated previously with a nonsteroidal antiandrogen, with evidence of disease progression subsequently; patients must be off use of anti-androgen for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration&lt;ul&gt;&lt;li&gt;Patients who demonstrate an anti-androgen withdrawal response, defined as a &gt;/=  25% decline in PSA within 4 to 6 week of stopping a nonsteroidal antiandrogen are not eligible until the PSA rises above the nadir observed after antiandrogen withdrawal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Castration levels of testosterone (&amp;lt; 50 ng/dl) within 2 weeks of registration&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) bone scan criteria or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during or after completing last therapy:&lt;ul&gt;&lt;li&gt;PSA: at least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, and each value &gt;/= 2.0 ng/ml&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Measurable disease: &gt;/= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion&lt;/li&gt;&lt;li&gt;Non-measurable (bone) disease: the appearance of two or more new areas of uptake on bone scan consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (eg, X-ray, CT or magnetic resonance imaging [MRI])&lt;/li&gt;&lt;li&gt;Must have &gt;/= 3 serum PSA values obtained over at least a 12 week period of time prior to registration, including the day of screening, to calculate a PSA doubling time&lt;ul&gt;&lt;li&gt;Note: PSA's are not required to be obtained at the same laboratory; use all PSA values that have been done in last 6 months to calculate PSA doubling time&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Life expectancy of at least 6 months&lt;/li&gt;&lt;li&gt;Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&lt;/li&gt;&lt;li&gt;White blood cell &gt;/= 2000/mm(3)&lt;/li&gt;&lt;li&gt;Absolute neutrophil count &gt;/= 1000/mm(3)&lt;/li&gt;&lt;li&gt;Hemoglobin (HgB) &gt;/= 9.0 mg/dl&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 100,000/mm(3)&lt;/li&gt;&lt;li&gt;Creatinine&amp;lt;/= 2.0 mg/dl&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST), alanine aminotransferase (ALT)&amp;lt;/= 2.5 x institutional upper limit of normal&lt;/li&gt;&lt;li&gt;Negative serology tests for human immunodeficiency virus (HIV) 1 and 2, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-T&lt;/li&gt;&lt;li&gt;Patients must be at least 4 weeks from any prior treatments and have recovered (to&amp;lt; grade 2) from acute toxicity attributed to this prior treatment&lt;/li&gt;&lt;li&gt;Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written informed consent form indicating such an understanding&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Serum testosterone at screening&amp;lt; 50 ng/dl&lt;/li&gt;&lt;li&gt;Prior cytotoxic chemotherapy within 6 months of registration&lt;/li&gt;&lt;li&gt;Radiation therapy within 4 weeks of registration is prohibited, or anticipated need             for radiation therapy (eg, imminent pathological fracture or spinal cord             compression) within 3 months of registration&lt;/li&gt;&lt;li&gt;Another malignancy other than non-melanoma skin cancer or carcinoma in situ of the             bladder.  Patients with a history of other curatively treated cancers are eligible&lt;/li&gt;&lt;li&gt;Known brain metastases&lt;/li&gt;&lt;li&gt;Any antibiotic therapy or evidence of infection within 1 week of registration&lt;/li&gt;&lt;li&gt;Small cell or other variant prostate cancer histology&lt;/li&gt;&lt;li&gt;Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivation&lt;/li&gt;&lt;li&gt;Symptomatic metastatic disease, as defined by the need for opioid analgesics for the treatment of pain attributed to a prostate cancer metastatic lesion; patients receiving opioids must receive approval from the principal investigator (PI) for eligibility&lt;/li&gt;&lt;li&gt;Patients may not have been treated with prior sipuleucel-T&lt;/li&gt;&lt;li&gt;Treatment with any of the following medications within 28 days of registration, or while on study, is prohibited:&lt;ul&gt;&lt;li&gt;Systemic corticosteroids (at doses over the equivalent of 1 mg prednisone daily); inhaled, intranasal or topical corticosteroids are acceptable&lt;/li&gt;&lt;li&gt;Prostate cancer (PC)-SPES&lt;/li&gt;&lt;li&gt;Saw palmetto&lt;/li&gt;&lt;li&gt;Megestrol&lt;/li&gt;&lt;li&gt;Ketoconazole&lt;/li&gt;&lt;li&gt;5-alpha-reductase inhibitors-patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study&lt;/li&gt;&lt;li&gt;Diethyl stilbestrol&lt;/li&gt;&lt;li&gt;Abiraterone&lt;/li&gt;&lt;li&gt;Any other hormonal agent or supplement being used with the intent of cancer treatment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (eg, imminent pathological fracture or spinal cord compression) within 3 months of registration&lt;/li&gt;&lt;li&gt;Major surgery within 4 weeks of registration is prohibited&lt;/li&gt;&lt;li&gt;Prior cytotoxic chemotherapy (eg, docetaxel, mitoxantrone, cabazitaxel) within 6 months of registration is prohibited&lt;/li&gt;&lt;li&gt;Patients with a history of life-threatening autoimmune disease&lt;/li&gt;&lt;li&gt;Patients who have undergone splenectomy&lt;/li&gt;&lt;li&gt;Patients must not have other active malignancies other than non-melanoma skin cancers or carcinoma in situ of the bladder; patients with a history of other cancers who have been adequately treated and have been recurrence-free for &gt;/= 3 years are eligible&lt;/li&gt;&lt;li&gt;Patients with known brain metastases&lt;/li&gt;&lt;li&gt;Any antibiotic therapy or evidence of infection within 1 week of registration&lt;/li&gt;&lt;li&gt;Any other medical intervention or condition, which, in the opinion of the PI could compromise patient safety or adherence with the study requirements&lt;/li&gt;&lt;li&gt;Patients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studies&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Measure immune responses following treatment with sipuleucel-T</Description><Timeframe>12 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression-free survival</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Time to radiographical disease progression</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Measure prostate-specific antigen (PSA) doubling time</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Number of circulating tumor cells</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>PAP-specific antibody and T-cell immune responses following treatment with sipuleucel-T and DNA vaccine will be summarized in tabular format</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Logistic regression analysis will be conducted to evaluate whether PAP-specific immune response is associated with prolonged (one-year) progression-free survival</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Logistic regression analysis will be conducted to evaluate whether baseline immune responses predict for immune responses elicited/augmented following treatment with sipuleucel-T +/- DNA vaccine</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>The detection of antigen spread to other prostate associated antigens, and the identification of specific antigens recognized, will be analyzed descriptively</Description><Timeframe>12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2018, results were published. No grade &amp;gt; 2  treatment-associated events were observed [&lt;ulink linkType="Reference" linkID="2032278"&gt;2032278&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to  test the effectiveness of      adding &lt;ulink linkType="Drug" linkID="57199"&gt;pTVG-HP&lt;/ulink&gt; vaccine with &lt;ulink linkType="Drug" linkID="17735"&gt;sipuleucel-T&lt;/ulink&gt; (Provenge) and to try to enhance patients own immune response against      prostate cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2018, results were published. In 11/18 patients, Th1-biased PAP-specific T-cell responses were detected and no statistical difference was observed between study arms. In patients who received pTVG-HP booster immunizations, higher titer antibody responses to prostatic acid phosphatase (PAP) were detected. Median time to progression was less than 6 months, and in both arms, there were no statistical difference. For all patients median overall survival was 28 months [&lt;ulink linkType="Reference" linkID="2032278"&gt;2032278&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of two arms.&lt;br/&gt;Arm 1: patients would receive &lt;ulink linkType="Drug" linkID="17735"&gt;sipuleucel-T&lt;/ulink&gt; iv per standard of care biweekly on weeks 0, 2, and 4.&lt;br/&gt;Arm 2: patients would receive &lt;ulink linkType="Drug" linkID="17735"&gt;sipuleucel-T&lt;/ulink&gt; as in arm 1 and pTVG-HP plasmid DNA vaccine intradermal on weeks 6, 8, 10, and 12, and then at 6 and 9 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized and received sipuleucel-T alone or followed by intradermal immunization with pTVG-HP DNA vaccine [&lt;ulink linkType="Reference" linkID="2032278"&gt;2032278&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Wisconsin Carbone Cancer Center</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3>53792</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3586">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="3571">Subjects with progressive disease despite therapy</SubSegment><SubSegment id="9106">Subjects with Rising PSA levels</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01706458</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="9129"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7049"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7088"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7089">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Prostate tumor" id="7045"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="7049"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="7088"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="9129"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="9131">Assessment of antibody titers</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3704"><Criterion>Subjects with Progressive Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3705">Subjects with rising PSA levels</SubCriterion><SubCriterion disease="Prostate tumor" id="3709">Subjects with progressive disease despite therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3731"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3733">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4845"><Criterion>Subjects with Advanced/Metastatic Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4847">Subjects with brain metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4899">Subjects with Auto-immune/Inflammatory diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4929"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4968">Subjects on prior/concurrent radiotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4969">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-06-12T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>46.39 Months</EnrollmentPeriod><EnrollmentRate>0.39 Patients/Month</EnrollmentRate><DateFirstReceived>2012-10-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-17T10:06:01Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-03-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-05-11T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>